Derivative works — US Patent 11878049

Defensive Disclosure Document: Derivative Works of US Patent 11878049

Patent: US11878049B1 - Mitapivat therapy and modulators of cytochrome P450
Assignee: Agios Pharmaceuticals Inc.
Current Date: 2026-05-19

This document details derivative variations of the core inventions claimed in US Patent 118778049. The purpose of this defensive disclosure is to establish prior art, thereby rendering obvious or non-novel any future incremental improvements by competitors that align with these described variations.

Claim 1 Derivatives: Method of treating PKD with mitapivat and a CYP3A4/5 inducer

Claim 1: A method of treating pyruvate kinase deficiency (PKD) in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof and an effective amount of an inducer of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 1.1: Accelerated Mitapivat Metabolism for Acute Dose Management

Derivation Axis: Operational Parameter Expansion (Extreme Scale: Rapid Induction)
Enabling Description: A method for rapidly accelerating the metabolism of mitapivat in a subject experiencing an acute adverse event or overdose, comprising administering a bolus dose of an ultra-strong, non-toxic CYP3A4/5 inducer, such as a synthetic pregnane X receptor (PXR) agonist (e.g., a novel small molecule with a PXR EC50 < 10 nM, developed for rapid onset of action), alongside standard supportive care. This bolus dose is followed by a continuous intravenous infusion of a moderate CYP3A4 inducer, such as phenobarbital at a dosage rate of 5-10 mg/kg/day, to maintain elevated CYP3A4/5 activity. The mitapivat dosage, typically mitapivat sulfate (N-[4-[[4-(cyclopropylmethyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide; sulfuric acid; trihydrate), is adjusted post-administration based on real-time plasma mitapivat concentration monitoring via liquid chromatography-mass spectrometry (LC-MS/MS) and phenotypic CYP3A4 activity assessment using a probe substrate. This rapid induction aims to decrease the area under the curve (AUC) of mitapivat by greater than 90% within 24 hours.

graph TD
    A[Subject with Mitapivat Toxicity] --> B{Administer Ultra-Strong CYP3A4/5 Inducer Bolus};
    B --> C[Initiate Continuous IV Infusion of Moderate CYP3A4 Inducer (e.g., Phenobarbital)];
    C --> D[Real-time Plasma Mitapivat Monitoring (LC-MS/MS)];
    D --> E{Assess CYP3A4 Activity (Probe Substrate)};
    E --> F[Adjust Mitapivat Dose (if still being administered) / Monitor for Resolution];
    F --> G[Resolution of Toxicity / Mitapivat Clearance];

Derivative 1.2: Oral Co-Formulation with pH-Triggered Inducer Release

Derivation Axis: Material & Component Substitution (Co-Formulation, Release Mechanism)
Enabling Description: A method of treating PKD in a subject comprising administering an oral pharmaceutical composition containing mitapivat (e.g., mitapivat sulfate) co-formulated with a pH-sensitive, enterically coated CYP3A4/5 inducer, such as microencapsulated rifampin. The enteric coating is designed to delay the release of rifampin until the intestinal lumen (pH > 5.5), ensuring spatial and temporal separation of absorption from the stomach-sensitive mitapivat absorption profile. The mitapivat component is formulated for immediate release. The microencapsulation of rifampin (e.g., using Eudragit® S100 or hydroxypropyl methylcellulose phthalate) provides a sustained release profile of the inducer over 6-8 hours, optimizing the induction effect on mitapivat metabolism while minimizing potential gastric irritation from rifampin.

graph TD
    A[Oral Co-Formulation Tablet] --> B{Stomach (pH 1-3)};
    B -- Mitapivat Dissolution (Immediate Release) --> C[Mitapivat Absorption];
    B -- Enteric Coated Inducer Intact --> D{Small Intestine (pH > 5.5)};
    D --> E[Inducer Coating Dissolution (Sustained Release)];
    E --> F[Rifampin Absorption (CYP3A4/5 Induction)];
    C & F --> G[Systemic Circulation: Mitapivat Metabolism Accelerated];

Derivative 1.3: Precision AgTech Application of Enzyme Modulation

Derivation Axis: Cross-Domain Application (AgTech)
Enabling Description: A method for optimizing the efficacy and environmental persistence of a systemic plant growth regulator (PGR) in high-value crops, analogous to mitapivat's therapeutic effect. The PGR, a novel indole-3-acetic acid derivative (e.g., N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)indole-3-acetamide), is applied as a foliar spray. To manage its degradation rate and prevent accumulation in soil or non-target plants, a synthetic microbial enzyme inducer (analogous to a CYP3A4/5 inducer), specifically a novel jasmonate derivative, is co-applied. This inducer upregulates the activity of plant cytochrome P450 monooxygenases (e.g., CYP71A1 or CYP707A1 orthologs involved in abscisic acid catabolism) within the target plant tissues, accelerating the hydroxylation and subsequent deactivation of the PGR. Dosage of the inducer is precisely controlled via drone-mounted variable-rate application systems, informed by real-time plant metabolite sensing.

graph TD
    A[PGR + Enzyme Inducer Solution] --> B(Drone Foliar Application);
    B --> C{Plant Leaf Surface};
    C --> D[PGR Absorption & Systemic Translocation];
    C --> E[Inducer Absorption & Cellular Uptake];
    E --> F[Upregulation of Plant P450s];
    D & F --> G[Accelerated PGR Hydroxylation/Deactivation];
    G --> H[Optimized PGR Efficacy & Reduced Environmental Persistence];

Derivative 1.4: AI-Optimized Adaptive Dosing of Mitapivat and Inducer

Derivation Axis: Integration with Emerging Tech (AI-driven optimization, IoT sensors)
Enabling Description: A closed-loop adaptive dosing system for PKD treatment. IoT-enabled wearable sensors continuously monitor key patient biomarkers (e.g., hemoglobin levels, reticulocyte count, 2,3-diphosphoglycerate levels, and real-time indirect indicators of mitapivat plasma concentration via a transdermal patch measuring skin metabolite efflux). This data is fed into an AI-driven pharmacokinetic/pharmacodynamic (PK/PD) model. The AI algorithm, utilizing deep reinforcement learning, dynamically calculates the optimal daily oral dose of mitapivat (e.g., mitapivat sulfate, 5-100 mg twice daily) and a moderate CYP3A4/5 inducer (e.g., a low dose of carbamazepine, 100-200 mg daily) to maintain target therapeutic windows for both the primary drug and the induction effect. The system provides real-time dosage adjustments to a smart medication dispenser, aiming to maximize hemoglobin response while minimizing side effects.

graph TD
    A[Patient] --> B(IoT Wearable Sensors: Hb, Retics, 2,3-DPG, Metabolite Efflux);
    B --> C{Cloud-based Data Aggregation};
    C --> D[AI-driven PK/PD Model (Deep Reinforcement Learning)];
    D --> E{Optimal Dose Calculation: Mitapivat & CYP3A4/5 Inducer};
    E --> F(Smart Medication Dispenser);
    F --> A;

Derivative 1.5: Mitapivat Formulation for "Soft Shutdown" with Inducer

Derivation Axis: The "Inverse" or Failure Mode (Controlled Deactivation)
Enabling Description: A mitapivat formulation designed for controlled deactivation or reduced efficacy upon co-administration with a specific CYP3A4/5 inducer, enabling a "soft shutdown" in response to emerging contraindications or a planned reduction in therapy. This formulation involves mitapivat as a pro-drug (e.g., a phosphate ester of mitapivat) that requires CYP3A4/5-mediated dephosphorylation for its activity. By co-administering a strong, yet short-acting, CYP3A4/5 inducer (e.g., intravenous rifampin, 600 mg once daily for 3 days), the enhanced CYP3A4/5 activity rapidly depletes the active mitapivat pro-drug, leading to a controlled reduction in its therapeutic effect rather than an abrupt cessation. This approach minimizes withdrawal symptoms or rebound effects. The inverse effect of the inducer here is that it promotes the deactivation of the mitapivat pro-drug, rather than the intended effect of the primary patent claim, which is to increase metabolism of active mitapivat.

graph TD
    A[Mitapivat Pro-drug] --> B{CYP3A4/5 Enzyme};
    B -- Dephosphorylation --> C[Active Mitapivat];
    C --> D[Therapeutic Effect];
    E[Short-Acting Strong CYP3A4/5 Inducer] --> B;
    B -- Increased Activity --> F[Accelerated Pro-drug Dephosphorylation];
    F --> G[Reduced Active Mitapivat Levels];
    G --> H[Controlled Reduction in Therapeutic Effect (Soft Shutdown)];

Claim 16 Derivatives: Method of treating PKD with mitapivat in the absence of a CYP3A4/5 inducer

Claim 16: A method of treating pyruvate kinase deficiency (PKD) in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof in the absence of an inducer of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 16.1: Mitapivat Administered with Enhanced Oral Bioavailability Formulation

Derivation Axis: Material & Component Substitution (Formulation, Excipients)
Enabling Description: A method of treating PKD in a subject comprising administering an effective amount of mitapivat (e.g., mitapivat sulfate) in a lipid-based drug delivery system (LBDDS), such as a self-emulsifying drug delivery system (SEDDS) or self-microemulsifying drug delivery system (SMEDDS). This formulation, consisting of mitapivat dissolved in a mixture of medium-chain triglycerides, a surfactant (e.g., polysorbate 80), and a co-surfactant (e.g., propylene glycol), enhances the oral bioavailability of mitapivat, reducing the need for dose adjustments in the absence of CYP3A4/5 inducers. The high bioavailability ensures consistent systemic exposure even in patients with naturally low CYP3A4/5 activity or those explicitly avoiding inducers. This approach minimizes the impact of inter-individual variability in CYP3A4/5 expression on drug efficacy.

graph TD
    A[Mitapivat + LBDDS Formulation] --> B(Oral Administration);
    B --> C{Gastrointestinal Tract};
    C --> D[Self-Emulsification/Microemulsification];
    D --> E[Enhanced Solubility & Permeation];
    E --> F[Increased Mitapivat Absorption];
    F --> G[Consistent Systemic Exposure (Absence of CYP3A4/5 Inducers)];

Derivative 16.2: Mitapivat Dosing Based on Genotypic CYP3A4/5 Phenotyping

Derivation Axis: Operational Parameter Expansion (Patient Stratification, Precision Medicine)
Enabling Description: A method of treating PKD where subjects undergo pre-treatment genotyping for common CYP3A4 and CYP3A5 polymorphisms (e.g., CYP3A4*1B, CYP3A5*3). Based on the determined genotype, subjects are stratified into "normal metabolizer," "intermediate metabolizer," and "poor metabolizer" categories for CYP3A4/5. For subjects identified as "normal" or "poor" metabolizers (where induction is not clinically desired or effective), a personalized initial mitapivat dose (e.g., mitapivat sulfate 5-50 mg daily) is established to ensure therapeutic efficacy in the absence of CYP3A4/5 inducers, minimizing the risk of sub-therapeutic levels or accumulation. This avoids the complexities of managing drug-drug interactions with inducers.

graph TD
    A[PKD Subject] --> B(Genotypic CYP3A4/5 Analysis);
    B --> C{Metabolizer Status (Normal, Intermediate, Poor)};
    C -- Normal/Poor Metabolizer --> D[Personalized Mitapivat Dose Calculation (No Inducer)];
    D --> E[Administer Mitapivat (Absence of Inducer)];
    E --> F[Therapeutic Effect in PKD];

Derivative 16.3: Veterinary Medicine Application in Absence of Enzyme Modulators

Derivation Axis: Cross-Domain Application (Veterinary Medicine)
Enabling Description: A method for treating chronic hemolytic anemia in companion animals (e.g., dogs, cats) suffering from a pyruvate kinase-like enzyme deficiency, where the animal is administered a PKR activator (e.g., a veterinary-grade mitapivat analog, N-(4-(4-(cyclobutylmethyl)piperazine-1-carbonyl)phenyl)naphthalene-2-sulfonamide) in the absence of known CYP3A4/5 inducers. The drug is administered orally as a flavored chewable tablet. To ensure consistent drug levels in a varied animal population with diverse metabolic rates, the dosing regimen is determined based on species-specific pharmacokinetic modeling, minimizing reliance on drug-drug interactions. Blood samples are taken weekly to monitor reticulocyte count and erythrocyte ATP levels, confirming therapeutic effect without external metabolic modulation.

graph TD
    A[Animal with Hemolytic Anemia] --> B{Diagnostic Testing (PKR Deficiency)};
    B --> C[Species-Specific PK Modeling];
    C --> D[Determine Mitapivat Analog Dose (No Inducer)];
    D --> E[Administer Flavored Chewable Tablet];
    E --> F[Weekly Blood Biomarker Monitoring];
    F --> G[Therapeutic Effect (Increased RBC Lifespan)];

Derivative 16.4: IoT-Monitored Adherence and Therapeutic Response Without Modulators

Derivation Axis: Integration with Emerging Tech (IoT Sensors, Digital Therapeutics)
Enabling Description: A digital therapeutic platform integrating IoT-enabled pill bottles for adherence monitoring and a smart blood glucose meter (adapted for Hb measurement) for real-time therapeutic response in PKD patients receiving mitapivat (e.g., mitapivat sulfate) in the absence of CYP3A4/5 inducers. The pill bottle records dose intake timestamps, and the glucose meter provides daily hemoglobin readings. This data is securely transmitted to a cloud platform, providing physicians with adherence metrics and therapeutic trends, allowing for proactive dose adjustments if needed, without confounding factors from enzyme modulators. Patient-facing apps provide reminders and educational content on PKD management.

graph TD
    A[PKD Patient] --> B(IoT Smart Pill Bottle);
    B --> C(Daily Mitapivat Dose Intake);
    C --> D(Smart Hb Meter);
    D --> E(Daily Hemoglobin Reading);
    B & D --> F{Cloud Platform (Adherence & Response Data)};
    F --> G[Physician Dashboard / Patient App];
    G --> H[Proactive Dose Adjustment (Mitapivat Only)];

Derivative 16.5: Mitapivat Sustained-Release for Stable PK in Absence of Inducers

Derivation Axis: The "Inverse" or Failure Mode (Minimizing Variability without Intervention)
Enabling Description: A sustained-release oral tablet formulation of mitapivat (e.g., mitapivat sulfate, 10-200 mg) designed to provide stable plasma concentrations over 24 hours, eliminating peak-and-trough fluctuations often seen with immediate-release formulations. This is achieved through a matrix tablet system using hydrophilic polymers (e.g., hydroxypropyl methylcellulose) that control drug release through swelling and erosion. The stable pharmacokinetic profile aims to reduce the variability in drug exposure that might otherwise necessitate CYP3A4/5 inducer co-administration for dose optimization, thereby providing a more predictable therapeutic effect in the absence of any enzymatic modulation. This provides a baseline, stable treatment, mitigating the "failure" of inconsistent drug levels without active intervention.

graph TD
    A[Mitapivat SR Tablet] --> B(Oral Administration);
    B --> C{Gastrointestinal Tract};
    C --> D[Polymer Matrix Hydration & Swelling];
    D --> E[Controlled Mitapivat Release (Diffusion & Erosion)];
    E --> F[Sustained Mitapivat Absorption];
    F --> G[Stable Plasma Concentration (24h) in Absence of Inducers];

Claim 22 Derivatives: Method of treating PKD with mitapivat and a CYP3A4/5 inhibitor

Claim 22: A method of treating pyruvate kinase deficiency (PKD) in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof and an effective amount of an inhibitor of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 22.1: Targeted CYP3A4/5 Inhibition for Reduced Mitapivat Dosing

Derivation Axis: Operational Parameter Expansion (Optimized Dosing, Reduced Primary Drug Load)
Enabling Description: A method for reducing the required dose of mitapivat (e.g., mitapivat sulfate) by co-administering a potent, irreversible CYP3A4 inhibitor, such as ritonavir (100 mg daily), allowing for significantly lower mitapivat dosages (e.g., 2.5-10 mg daily) while achieving equivalent or superior therapeutic exposure. The irreversible inhibition of CYP3A4/5 by ritonavir prolongs the half-life of mitapivat, reducing the overall drug burden on the patient and potentially mitigating dose-dependent side effects. The mitapivat dose is calculated to achieve target Cmin levels in the presence of maximal enzyme inhibition, aiming for a 75-90% reduction in mitapivat daily dose compared to monotherapy.

graph TD
    A[PKD Subject] --> B(Administer Ritonavir (Irreversible CYP3A4/5 Inhibitor));
    B --> C[CYP3A4/5 Enzyme Inactivation];
    C --> D[Reduced Mitapivat Metabolism Rate];
    D --> E[Administer Reduced Mitapivat Dose];
    E --> F[Elevated & Prolonged Mitapivat Plasma Levels];
    F --> G[Therapeutic Effect in PKD with Lower Mitapivat Burden];

Derivative 22.2: Transdermal Patch for Controlled Inhibitor Delivery

Derivation Axis: Material & Component Substitution (Delivery Mechanism)
Enabling Description: A method of treating PKD where mitapivat (e.g., mitapivat sulfate) is administered orally, and a sustained-release transdermal patch delivers a moderate CYP3A4/5 inhibitor, such as diltiazem (e.g., 180-240 mg/day equivalent over 24 hours), to maintain a consistent inhibitory effect. The transdermal patch system uses a pressure-sensitive adhesive matrix containing diltiazem and penetration enhancers (e.g., oleic acid, ethanol) to ensure steady systemic absorption. This avoids daily oral dosing of the inhibitor, improving adherence and reducing peak-and-trough fluctuations in inhibitor concentration, leading to more predictable mitapivat exposure.

graph TD
    A[PKD Subject] --> B(Oral Mitapivat Administration);
    B --> C(Apply Transdermal Patch with CYP3A4/5 Inhibitor (Diltiazem));
    C --> D[Controlled Inhibitor Release (24h)];
    D --> E[Consistent Systemic Diltiazem Levels];
    E --> F[Stable CYP3A4/5 Inhibition];
    F --> G[Predictable Mitapivat Plasma Concentration];

Derivative 22.3: Industrial Bioreactor Optimization via Enzyme Inhibition

Derivation Axis: Cross-Domain Application (Industrial Chemistry)
Enabling Description: A method for extending the half-life and yield of a desired biocatalytic product (analogous to mitapivat's therapeutic effect) in an industrial fermentation bioreactor. The bioreactor utilizes a genetically engineered microbial strain producing a key enzyme (analogous to PKR) and a secondary enzyme responsible for its degradation (analogous to CYP3A4/5). To enhance product yield, a non-toxic, competitive enzyme inhibitor (analogous to a CYP3A4/5 inhibitor), such as a synthetic transition state analog, is continuously infused into the bioreactor at controlled concentrations (e.g., 10-50 µM). This inhibitor specifically targets the degradation enzyme, reducing the breakdown of the desired product and increasing its accumulation, thus improving process efficiency.

graph TD
    A[Industrial Bioreactor] --> B(Microbial Culture: Product & Degradation Enzymes);
    B --> C[Continuous Infusion of Enzyme Inhibitor];
    C --> D[Inhibition of Degradation Enzyme];
    D --> E[Reduced Product Breakdown];
    E --> F[Increased Product Yield & Stability];

Derivative 22.4: Blockchain for Secure Inhibitor-Enhanced Mitapivat Prescription and Supply Chain

Derivation Axis: Integration with Emerging Tech (Blockchain for Supply Chain/Prescription)
Enabling Description: A blockchain-enabled system for managing the prescription and supply chain of mitapivat in combination with CYP3A4/5 inhibitors. Each prescription (mitapivat sulfate + a strong inhibitor like itraconazole) is recorded as a smart contract on a private blockchain, linking patient ID, physician, drug details, dosage, and planned interaction. Drug manufacturers and distributors record batch numbers, expiry dates, and supply movements as transactions on the chain. This ensures tamper-proof traceability, verifies drug authenticity, prevents illicit diversion of potent inhibitors, and provides an immutable audit trail for regulatory compliance in managing drug-drug interactions. Patient consent for data access is managed via cryptographic keys.

graph TD
    A[Physician] --> B(Smart Contract: Rx Mitapivat + Inhibitor);
    B --> C[Patient Blockchain Wallet (Consent)];
    C --> D[Pharmacy (Dispense)];
    D --> E[Supply Chain (Manufacturer, Distributor, Pharmacy)];
    E -- Transactions: Batch, Expiry, Movement --> F[Private Blockchain Ledger];
    F --> G[Regulatory Audit & Authenticity Verification];

Derivative 22.5: Low-Dose Mitapivat with Microdosed Inhibitor for Long-Term Maintenance

Derivation Axis: The "Inverse" or Failure Mode (Low-Power/Limited-Functionality for Maintenance)
Enabling Description: A long-term maintenance therapy for PKD using ultra-low doses of mitapivat (e.g., mitapivat sulfate, 1 mg daily) combined with microdoses of a mild, reversible CYP3A4/5 inhibitor (e.g., cimetidine, 50 mg daily). This regimen aims to provide a continuous, low-level activation of PKR, sufficient to prevent relapse and maintain stable hemoglobin levels, without the robust effects of a full therapeutic dose. The microdosed inhibitor acts to slightly extend the mitapivat half-life, providing a "limited-functionality" boost to exposure that allows the ultra-low mitapivat dose to remain effective. This minimizes potential side effects of both drugs, suitable for long-term chronic management, acting as a controlled, mild enhancement rather than a full therapeutic intervention.

graph TD
    A[PKD Patient (Maintenance)] --> B(Administer Ultra-Low Mitapivat Dose);
    B --> C(Co-administer Microdosed Mild CYP3A4/5 Inhibitor);
    C --> D[Slight Extension of Mitapivat Half-Life];
    D --> E[Sustained Low-Level PKR Activation];
    E --> F[Prevention of Relapse / Stable Hb (Limited Functionality)];

Claim 37 Derivatives: Method of treating PKD with mitapivat in the absence of a CYP3A4/5 inhibitor

Claim 37: A method of treating pyruvate kinase deficiency (PKD) in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof in the absence of an inhibitor of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 37.1: Mitapivat with Biofeedback-Controlled Dosing in High Metabolizers

Derivation Axis: Operational Parameter Expansion (Individualized Dosing, High Metabolizers)
Enabling Description: A method of treating PKD in subjects identified as ultra-rapid CYP3A4/5 metabolizers (e.g., via dextromethorphan breath test or genetic sequencing showing multiple functional CYP3A4/5 alleles) where mitapivat (e.g., mitapivat sulfate) is administered without a CYP3A4/5 inhibitor. To compensate for rapid metabolism, the mitapivat is administered at higher-than-standard daily doses (e.g., 200-400 mg daily) and/or more frequently (e.g., three times daily). Dosing is fine-tuned using a biofeedback system that monitors real-time reticulocyte count and erythrocyte ATP levels from a minimally invasive dermal sensor, providing immediate feedback for dose adjustment to maintain therapeutic efficacy in the absence of metabolic inhibition.

graph TD
    A[PKD Subject (Ultra-Rapid Metabolizer)] --> B(Initial High/Frequent Mitapivat Dose);
    B --> C{Minimally Invasive Dermal Sensor: Retic Count, ATP Levels};
    C --> D[Biofeedback System];
    D --> E{Adjust Mitapivat Dose/Frequency (No Inhibitor)};
    E --> F[Sustained Therapeutic Effect];

Derivative 37.2: Mitapivat with pH-Independent Solubilization for Predictable Absorption

Derivation Axis: Material & Component Substitution (Formulation, Solubility Enhancement)
Enabling Description: A method of treating PKD by administering mitapivat (e.g., mitapivat sulfate) formulated as an amorphous solid dispersion (ASD) with a high glass transition temperature polymer (e.g., hydroxypropyl methylcellulose acetate succinate, HPMCAS). This ASD formulation ensures pH-independent solubilization and supersaturation in the gastrointestinal tract, leading to consistent and predictable oral absorption of mitapivat. This robust absorption profile negates the need for CYP3A4/5 inhibitors to boost bioavailability, allowing for reliable therapeutic outcomes across varying gastric pH environments and avoiding potential drug-drug interaction complexities.

graph TD
    A[Mitapivat ASD Tablet] --> B(Oral Administration);
    B --> C{GI Tract (Varying pH)};
    C --> D[pH-Independent Solubilization (Supersaturation)];
    D --> E[Consistent Mitapivat Absorption];
    E --> F[Predictable Plasma Levels (Absence of CYP3A4/5 Inhibitors)];

Derivative 37.3: Aquaculture Growth Promoter (Absence of Enzyme Inhibitors)

Derivation Axis: Cross-Domain Application (Aquaculture)
Enabling Description: A method for promoting growth and enhancing disease resistance in farmed aquatic species (e.g., salmon, shrimp) by administering a feed additive containing a pyruvate kinase activator (e.g., a fish-specific mitapivat analog, N-(4-(4-(methylcyclopropyl)piperazine-1-carbonyl)phenyl)indole-5-sulfonamide) in the absence of any enzyme inhibitors that would prolong its systemic presence. The activator is incorporated into fish feed pellets at a concentration of 10-50 mg/kg feed. Its intrinsic metabolic clearance rate in the fish liver is leveraged to ensure tissue residue levels remain below regulatory limits, relying solely on the species' natural detoxification pathways without external modulation to avoid accumulation.

graph TD
    A[Aquatic Species] --> B(Feed Pellet with Mitapivat Analog);
    B --> C{Digestion & Absorption};
    C --> D[Systemic PKR Activation];
    D --> E[Natural Hepatic Clearance (No Inhibitor)];
    E --> F[Enhanced Growth / Disease Resistance (Controlled Persistence)];

Derivative 37.4: Telemedicine Platform with Prescriptive Analytics for Monotherapy

Derivation Axis: Integration with Emerging Tech (Telemedicine, AI Prescriptive Analytics)
Enabling Description: A telemedicine platform that leverages AI-driven prescriptive analytics to manage PKD patients on mitapivat monotherapy (e.g., mitapivat sulfate, 50-100 mg twice daily), specifically when CYP3A4/5 inhibitors are absent. The platform integrates patient-reported outcomes (PROs), home blood test results (e.g., complete blood count), and anonymized historical patient data. The AI generates personalized dosing recommendations and identifies potential non-drug-related factors (e.g., diet, hydration) influencing treatment efficacy, ensuring optimal therapeutic outcomes without needing to manage drug-drug interactions with inhibitors. Virtual consultations facilitate remote monitoring and adjustments.

graph TD
    A[PKD Patient Home] --> B(Patient Reported Outcomes (PROs));
    B --> C(Home Blood Test Results (CBC));
    C --> D{Telemedicine Platform (Secure Data)};
    D --> E[AI Prescriptive Analytics Engine];
    E --> F{Personalized Mitapivat Dose Recommendation (No Inhibitor)};
    F --> G[Virtual Physician Consultation];
    G --> A;

Derivative 37.5: Auto-Degrading Mitapivat for Environmental Safety

Derivation Axis: The "Inverse" or Failure Mode (Safe Environmental Degradation)
Enabling Description: A mitapivat formulation (e.g., mitapivat sulfate) designed with environmentally degradable linkers (e.g., ester or amide bonds susceptible to ubiquitous environmental esterases or peptidases) within its structure. While administered orally, the intent is that any unmetabolized drug excreted into the wastewater system or any residual drug not fully absorbed by the patient, rapidly degrades into inactive, non-toxic metabolites under common environmental conditions (e.g., sunlight, microbial action, pH variation), without the need for biological enzyme inhibitors to control its persistence. This is a "safe failure" mode for environmental impact, where the drug does not persist in the ecosystem.

graph TD
    A[Mitapivat (Degradable Linkers)] --> B(Patient Administration);
    B --> C{Metabolism / Excretion};
    C --> D[Excreted Mitapivat];
    D --> E{Environmental Exposure (UV, Microbes, pH)};
    E --> F[Rapid Hydrolysis/Degradation of Linkers];
    F --> G[Inactive, Non-Toxic Metabolites (Safe Failure)];

Claim 43 Derivatives: Method of treating Sickle Cell Disease (SCD) with mitapivat and a CYP3A4/5 inducer

Claim 43: A method of treating sickle cell disease in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof and an effective amount of an inducer of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 43.1: Sequential Dosing with Genetic Inducer Optimization

Derivation Axis: Operational Parameter Expansion (Sequential Dosing, Genetic Tailoring)
Enabling Description: A method of treating SCD where a subject's genetic profile for CYP3A4/5 inducibility (e.g., PXR gene polymorphisms) is determined. Based on this, a highly individualized, sequential dosing regimen is designed. For subjects with robust inducibility, a rapid-acting CYP3A4/5 inducer (e.g., modafinil, 200 mg daily) is administered for a pre-determined period (e.g., 3-5 days) to rapidly achieve maximal induction, followed by the introduction of mitapivat (e.g., mitapivat sulfate, 50-100 mg twice daily) at a dose adjusted to the established induction level. This ensures efficient mitapivat clearance from the outset, minimizing accumulation and side effects in the highly inducible population, allowing for precise control over drug exposure kinetics.

graph TD
    A[SCD Subject] --> B(Genetic CYP3A4/5 Inducibility Test);
    B --> C{Robust Inducibility Identified};
    C --> D[Administer Rapid-Acting CYP3A4/5 Inducer (Pre-induction phase)];
    D --> E[Assess Maximal Induction (Probe Substrate)];
    E --> F[Initiate Mitapivat Administration (Dose Adjusted to Induction)];
    F --> G[Therapeutic Effect in SCD with Controlled Clearance];

Derivative 43.2: Co-Crystallization of Mitapivat and Inducer

Derivation Axis: Material & Component Substitution (Solid State Chemistry)
Enabling Description: A method of treating SCD using a pharmaceutical co-crystal comprising mitapivat (e.g., mitapivat free base) and a selected CYP3A4/5 inducer (e.g., carbamazepine). The co-crystal structure is engineered to provide improved dissolution rates and intrinsic stability for both components compared to individual compounds or simple mixtures, ensuring consistent bioavailability. This co-crystallization enables fixed-dose combination therapy in a single oral dosage form, simplifying administration and guaranteeing a precise stoichiometric ratio of drug and inducer for a predictable drug-drug interaction profile, which is critical in managing SCD.

graph TD
    A[Mitapivat Free Base] --> B(Co-crystallization Process);
    C[CYP3A4/5 Inducer (Carbamazepine)] --> B;
    B --> D[Mitapivat-Inducer Co-crystal];
    D --> E(Oral Administration as Tablet);
    E --> F[Enhanced Dissolution & Stability];
    F --> G[Consistent Bioavailability of Both Components];
    G --> H[Therapeutic Effect in SCD via Controlled Induction];

Derivative 43.3: Space Medicine - Radiation Mitigation with Enzyme Modulation

Derivation Axis: Cross-Domain Application (Aerospace/Space Medicine)
Enabling Description: A method for mitigating cellular damage from cosmic radiation in astronauts during long-duration space missions, using a primary radioprotective agent (analogous to mitapivat, e.g., an NRF2 activator) whose metabolism is enhanced by a CYP3A4/5-like enzyme inducer. The NRF2 activator is administered as part of the daily supplement regimen. A specific, potent CYP3A4 inducer, bioengineered for enhanced stability in microgravity (e.g., a lyophilized fungal metabolite inducer), is co-administered to rapidly clear any accumulated NRF2 activator or its potentially toxic metabolites, maintaining its therapeutic window and reducing systemic burden. This controlled metabolism is crucial in the resource-limited and physiologically altered environment of space.

graph TD
    A[Astronaut] --> B(Daily Radioprotective Agent (NRF2 Activator));
    B --> C(Co-administer Microgravity-Stable CYP3A4 Inducer);
    C --> D[Accelerated NRF2 Activator Metabolism];
    D --> E[Prevention of Accumulation/Toxicity];
    E --> F[Enhanced Radiation Mitigation & Cellular Protection];

Derivative 43.4: Real-time Metabolomic Profiling for Inducer-Adjusted Therapy

Derivation Axis: Integration with Emerging Tech (IoT Sensors, Advanced Diagnostics)
Enabling Description: A personalized treatment approach for SCD involving mitapivat (e.g., mitapivat sulfate) and a CYP3A4/5 inducer. Patients use a portable breath analyzer integrated with an IoT platform to provide daily metabolomic profiles (e.g., volatile organic compounds, VOCs, linked to mitapivat metabolism). This data, combined with non-invasive pulse oximetry for oxygen saturation (a key SCD biomarker), is analyzed by an AI algorithm. The AI uses these real-time metabolomic and physiological markers to recommend precise, adaptive adjustments to the inducer dose (e.g., rifampin, 300-600 mg daily) to maintain optimal mitapivat clearance, ensuring therapeutic efficacy and minimizing vaso-occlusive crises.

graph TD
    A[SCD Patient] --> B(Portable Breath Analyzer (Metabolomics));
    B --> C(Non-invasive Pulse Oximetry (O2 Sat));
    C --> D{IoT Platform};
    D --> E[AI Metabolomic & Physiological Analysis];
    E --> F{Adaptive CYP3A4/5 Inducer Dose Recommendation};
    F --> G[Optimal Mitapivat Clearance & SCD Management];

Derivative 43.5: "Fail-Safe" Inducer Deactivation for Over-Induction Prevention

Derivation Axis: The "Inverse" or Failure Mode (Safe Deactivation)
Enabling Description: A CYP3A4/5 inducer (e.g., rifampin) engineered as a photosensitive pro-drug, designed to undergo rapid photodegradation to an inactive metabolite upon exposure to a specific wavelength of light (e.g., UV-A). In cases of excessive or unwanted CYP3A4/5 induction (leading to sub-therapeutic mitapivat levels in SCD patients), the patient could be exposed to a controlled, external light source (e.g., a wearable phototherapy device). This would rapidly deactivate the inducer, allowing mitapivat levels to recover, providing a rapid "fail-safe" mechanism to reverse over-induction without requiring additional pharmacological interventions.

graph TD
    A[Photosensitive CYP3A4/5 Inducer Pro-drug] --> B(Oral Administration);
    B --> C[CYP3A4/5 Induction];
    C -- Excessive Induction --> D[Sub-therapeutic Mitapivat Levels];
    D --> E(Activation of Phototherapy Device);
    E --> F[Controlled Light Exposure];
    F --> G[Rapid Inducer Photodegradation (Fail-Safe)];
    G --> H[CYP3A4/5 Activity Reverts / Mitapivat Levels Recover];

Claim 50 Derivatives: Method of treating SCD with mitapivat in the absence of a CYP3A4/5 inducer

Claim 50: A method of treating sickle cell disease in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof in the absence of an inducer of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 50.1: Mitapivat with Targeted Erythroid Delivery System

Derivation Axis: Material & Component Substitution (Targeted Delivery)
Enabling Description: A method of treating SCD where mitapivat (e.g., mitapivat sulfate) is encapsulated within a targeted delivery system, such as antibody-conjugated liposomes or nanoparticles designed to selectively bind to markers on developing erythroid cells (e.g., transferrin receptor 1). This targeted delivery concentrates mitapivat in the red blood cell precursors, maximizing its effect on PKR activation and hemoglobin production, while minimizing systemic exposure and metabolism. This approach achieves therapeutic efficacy in the absence of CYP3A4/5 inducers by ensuring efficient drug utilization and reducing the impact of first-pass metabolism.

graph TD
    A[Mitapivat-Loaded Nanoparticles] --> B(IV Administration);
    B --> C{Systemic Circulation};
    C --> D[Targeted Binding to Erythroid Precursors];
    D --> E[Selective Mitapivat Uptake];
    E --> F[Localized PKR Activation & Hemoglobin Production (No Inducer)];
    F --> G[Therapeutic Effect in SCD];

Derivative 50.2: Mitapivat Microdosing with Prolonged Treatment Regimen

Derivation Axis: Operational Parameter Expansion (Extended Treatment, Microdosing)
Enabling Description: A method of treating SCD where mitapivat (e.g., mitapivat sulfate) is administered at a significantly reduced daily dose (e.g., 5-10 mg daily) over a prolonged treatment period (e.g., >12 months), in the absence of CYP3A4/5 inducers. This microdosing regimen aims to provide a continuous, low-level stimulation of PKR, slowly accumulating beneficial effects on erythrocyte lifespan and reducing sickling events over time. The absence of inducers ensures that even low doses maintain predictable systemic exposure, favoring a gradual, sustained therapeutic improvement without acute pharmacological interventions.

graph TD
    A[SCD Subject] --> B(Initiate Microdosed Mitapivat (No Inducer));
    B --> C[Long-Term Daily Administration];
    C --> D[Continuous Low-Level PKR Activation];
    D --> E[Gradual Improvement in RBC Health / Reduced Sickling];
    E --> F[Sustained Therapeutic Benefit in SCD (>12 months)];

Derivative 50.3: Marine Biology - Algal Bloom Control (Absence of Modulators)

Derivation Axis: Cross-Domain Application (Marine Biology/Environmental Remediation)
Enabling Description: A method for controlling harmful algal blooms (HABs) in enclosed aquatic environments (e.g., aquaculture ponds, small lakes) by introducing a targeted enzyme activator (analogous to mitapivat, e.g., a phytase or phosphatase activator) that disrupts key metabolic pathways in problematic algal species, leading to their selective reduction. This activator is deployed in a slow-release granular form. No enzyme inducers (which would accelerate its degradation) are used, allowing the activator to exert its effect through its intrinsic half-life and concentration, leveraging the natural enzymatic inhibition present in the target algae for prolonged action, thereby managing the HAB without external metabolic interference.

graph TD
    A[Aquatic Environment with Algal Bloom] --> B(Deploy Slow-Release Enzyme Activator Granules);
    B --> C[Activator Dissolution & Algal Uptake];
    C --> D[Disruption of Algal Metabolic Pathways];
    D --> E[Algal Bloom Reduction (No Inducer)];
    E --> F[Environmental Remediation (Activator's Intrinsic Persistence)];

Derivative 50.4: Digital Twin for Predictive SCD Response (No Inducers)

Derivation Axis: Integration with Emerging Tech (AI/Digital Twin)
Enabling Description: A "digital twin" of an SCD patient created using computational modeling that integrates comprehensive patient data (genomics, clinical history, previous treatment responses, dietary intake, physical activity). This digital twin is used to predict the individual's pharmacokinetic and pharmacodynamic response to mitapivat (e.g., mitapivat sulfate) monotherapy, in the absence of CYP3A4/5 inducers. The model simulates various dosing regimens and predicts outcomes like hemoglobin levels, sickling crises frequency, and erythrocyte ATP levels, allowing for highly personalized treatment optimization without real-world experimentation, particularly beneficial for sensitive patient populations where drug interactions are undesirable.

graph TD
    A[SCD Patient Data] --> B(Digital Twin Creation (Genomics, Clinical, etc.));
    B --> C[PK/PD Modeling of Mitapivat Monotherapy];
    C --> D[Simulation of Dosing Regimens];
    D --> E[Predictive Outcomes (Hb, Crises, ATP)];
    E --> F[Personalized Mitapivat Dose Optimization (No Inducer)];

Derivative 50.5: Placebo-Controlled Crossover Trial with Mitapivat Alone

Derivation Axis: The "Inverse" or Failure Mode (Controlled Research/Baseline Functionality)
Enabling Description: A rigorously designed, placebo-controlled, double-blind, crossover clinical trial for SCD patients comparing mitapivat (e.g., mitapivat sulfate, 100 mg twice daily) monotherapy against placebo, specifically excluding subjects on any known CYP3A4/5 inducers. The "failure mode" here is the absence of any active drug in the placebo arm, establishing a baseline for the inherent therapeutic effect of mitapivat without external modulation. This design precisely isolates the intrinsic activity of mitapivat in improving SCD biomarkers (e.g., hemoglobin, hemolytic markers, vaso-occlusive crisis frequency) and provides a clear understanding of its baseline functionality, crucial for future drug development or dose-response modeling.

graph TD
    A[SCD Patient Cohort (No Inducer)] --> B{Randomize};
    B -- Arm 1 --> C[Mitapivat Monotherapy (100mg BID)];
    B -- Arm 2 --> D[Placebo];
    C --> E[Measure Hb, Hemolysis Markers, VOCs];
    D --> E;
    E -- Crossover --> F[Analyze Baseline Mitapivat Efficacy (Absence of Inducer)];

Claim 54 Derivatives: Method of treating SCD with mitapivat and a CYP3A4/5 inhibitor

Claim 54: A method of treating sickle cell disease in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof and an effective amount of an inhibitor of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 54.1: Mitapivat Dose Escalation with Concurrent Inhibitor Titration

Derivation Axis: Operational Parameter Expansion (Adaptive Dosing, Titration Strategy)
Enabling Description: A method for treating SCD using a carefully controlled dose escalation of mitapivat (e.g., mitapivat sulfate, starting 5 mg twice daily up to 100 mg twice daily) concurrently with a dose titration of a moderate CYP3A4/5 inhibitor (e.g., fluconazole, starting 50 mg daily up to 200 mg daily). The titration schedule is based on a predictive algorithm that correlates mitapivat plasma levels (measured by dried blood spot sampling) with changes in hemoglobin and 2,3-DPG levels, optimizing the inhibitory effect to achieve desired mitapivat exposure while minimizing inhibitor-related side effects. This adaptive approach ensures a stable therapeutic window despite individual variability in metabolism.

graph TD
    A[SCD Subject] --> B{Initial Low Doses: Mitapivat + Inhibitor};
    B --> C[Dried Blood Spot: Mitapivat Levels];
    C --> D[Measure Hb, 2,3-DPG];
    D --> E[Predictive Dosing Algorithm];
    E --> F{Titrate Mitapivat & Inhibitor Doses};
    F --> G[Achieve Optimal Mitapivat Exposure & Therapeutic Effect];

Derivative 54.2: Polymeric Micelles for Co-Delivery of Mitapivat and Inhibitor

Derivation Axis: Material & Component Substitution (Nanotechnology, Co-Delivery)
Enabling Description: A method of treating SCD by co-administering mitapivat (e.g., mitapivat free base) and a lipophilic CYP3A4/5 inhibitor (e.g., ketoconazole) encapsulated within biodegradable polymeric micelles. The micelles, formed from amphiphilic block copolymers (e.g., PEG-PLA), co-load both drugs, allowing for improved solubility, enhanced cellular uptake, and simultaneous release kinetics. This co-delivery system ensures that the inhibitor is present at therapeutic concentrations alongside mitapivat, achieving a synergistic effect by enhancing mitapivat's bioavailability and prolonging its action within the target cells, specifically erythrocytes, crucial for SCD treatment.

graph TD
    A[Mitapivat Free Base] --> B(Polymeric Micelle Formulation);
    C[Lipophilic CYP3A4/5 Inhibitor (Ketoconazole)] --> B;
    B --> D[Co-loaded Polymeric Micelles];
    D --> E(IV or Oral Administration);
    E --> F[Enhanced Solubility & Cellular Uptake];
    F --> G[Simultaneous Drug Release & Synergistic Effect];
    G --> H[Therapeutic Effect in SCD];

Derivative 54.3: Agricultural Biofortification with Nutrient Absorption Modulation

Derivation Axis: Cross-Domain Application (Agri-Food/Biofortification)
Enabling Description: A method for enhancing the bioavailability and retention of essential micronutrients (e.g., iron, zinc, analogous to mitapivat) in biofortified food crops, by co-applying a natural plant enzyme inhibitor (analogous to CYP3A4/5 inhibitor, e.g., a phenolic compound from plant extracts) to the soil or foliage. This inhibitor reduces the activity of plant enzymes (e.g., certain oxidases or reductases) responsible for metabolizing or sequestering the micronutrients within the plant. By slowing down this metabolism, the micronutrient remains in a more bioavailable form for longer, increasing the nutritional value of the harvested crop for human consumption.

graph TD
    A[Biofortified Crop] --> B(Micronutrient Uptake);
    C[Co-Apply Plant Enzyme Inhibitor];
    C --> D[Inhibition of Plant Metabolizing Enzymes];
    D --> E[Prolonged Bioavailable Micronutrient Form];
    E --> F[Increased Nutritional Value (Biofortification)];

Derivative 54.4: AI-Driven Therapeutic Drug Monitoring (TDM) and Inhibitor Adjustment

Derivation Axis: Integration with Emerging Tech (AI, TDM)
Enabling Description: A TDM system for SCD patients receiving mitapivat (e.g., mitapivat sulfate) and a CYP3A4/5 inhibitor. Patient plasma samples are analyzed via a portable LC-MS/MS device. An AI algorithm, trained on population PK data and individual patient responses, interprets the mitapivat concentrations and, if necessary, suggests precise adjustments to the CYP3A4/5 inhibitor dose (e.g., clarithromycin, 250-500 mg daily or twice daily). This real-time feedback loop, based on quantitative drug levels, optimizes the drug-drug interaction to maintain mitapivat within its therapeutic window, particularly important for SCD patients where consistent exposure is vital to prevent crises.

graph TD
    A[SCD Patient] --> B(Mitapivat & Inhibitor Administration);
    B --> C(Portable LC-MS/MS: Plasma Mitapivat Levels);
    C --> D[AI TDM Algorithm];
    D --> E{Optimal Inhibitor Dose Adjustment};
    E --> F[Physician / Patient (Feedback)];
    F --> A;

Derivative 54.5: Mitapivat & Inhibitor Regimen for Renal-Impaired Patients (Reduced Functionality)

Derivation Axis: The "Inverse" or Failure Mode (Limited Functionality for Specific Population)
Enabling Description: A specialized mitapivat (e.g., mitapivat sulfate) and CYP3A4/5 inhibitor (e.g., fluconazole) dosing regimen specifically tailored for SCD patients with moderate to severe renal impairment, where drug elimination is compromised. In this "reduced functionality" patient group, both mitapivat and the inhibitor doses are significantly lowered (e.g., 50% reduction for mitapivat, 25% reduction for fluconazole) to prevent accumulation. The inhibitor is chosen for minimal renal excretion, and the dose is adjusted to achieve a lower, yet still therapeutically effective, mitapivat exposure, reflecting a cautious approach to minimize adverse effects in a vulnerable population where clearance pathways are already "failing."

graph TD
    A[SCD Patient with Renal Impairment] --> B(Reduced Dose Mitapivat & Inhibitor);
    B --> C[Compromised Renal Clearance];
    C --> D[Lower Target Mitapivat Exposure];
    D --> E[Therapeutic Effect with Minimized Accumulation (Reduced Functionality)];
    E --> F[Close Monitoring of Renal Function & Drug Levels];

Claim 61 Derivatives: Method of treating SCD with mitapivat in the absence of a CYP3A4/5 inhibitor

Claim 61: A method of treating sickle cell disease in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof in the absence of an inhibitor of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 61.1: Chrono-Pharmacological Dosing of Mitapivat for SCD Monotherapy

Derivation Axis: Operational Parameter Expansion (Temporal Dosing, Circadian Rhythms)
Enabling Description: A method of treating SCD by administering mitapivat (e.g., mitapivat sulfate) in the absence of CYP3A4/5 inhibitors, with a chrono-pharmacological dosing schedule. Mitapivat is administered once daily at a specific time (e.g., 6 PM or 6 AM), chosen to coincide with the lowest physiological activity of CYP3A4/5 (which exhibits circadian rhythmicity) and/or optimal erythrocyte turnover rates in SCD patients. This precise timing maximizes mitapivat's systemic exposure and its therapeutic effect on PKR activation without external inhibition, leveraging the body's natural metabolic fluctuations to optimize drug efficacy.

graph TD
    A[SCD Subject] --> B(Determine Optimal Circadian Dosing Window);
    B --> C[Administer Mitapivat Once Daily (Specific Time)];
    C --> D[Leverage Natural Low CYP3A4/5 Activity];
    D --> E[Maximized Mitapivat Exposure (No Inhibitor)];
    E --> F[Enhanced Therapeutic Effect in SCD];

Derivative 61.2: Mitapivat in a High-Density Amorphous Microparticle Formulation

Derivation Axis: Material & Component Substitution (Advanced Formulation)
Enabling Description: A method of treating SCD where mitapivat (e.g., mitapivat free base) is formulated into high-density amorphous microparticles via spray drying with a co-polymer (e.g., PVPVA 64). These microparticles are then incorporated into an oral capsule. The small particle size and amorphous state enhance dissolution rate and saturation solubility, leading to rapid and complete absorption of mitapivat even in the absence of CYP3A4/5 inhibitors. The high density ensures consistent gastric emptying and reduces inter-patient variability in absorption, providing predictable therapeutic levels without reliance on metabolic inhibition.

graph TD
    A[Mitapivat Free Base + Polymer] --> B(Spray Drying);
    B --> C[High-Density Amorphous Microparticles];
    C --> D(Oral Capsule Formulation);
    D --> E[Rapid Dissolution & Complete Absorption (No Inhibitor)];
    E --> F[Predictable Mitapivat Plasma Levels];
    F --> G[Therapeutic Effect in SCD];

Derivative 61.3: Environmental Toxin Bioremediation (Absence of Metabolic Inhibitors)

Derivation Axis: Cross-Domain Application (Environmental Engineering)
Enabling Description: A method for bioremediation of a specific recalcitrant environmental toxin (analogous to mitapivat, e.g., a chlorinated organic compound) using a naturally occurring microbial consortium. This consortium possesses a primary detoxification pathway for the toxin that is regulated by a key enzyme. The method involves optimizing environmental conditions (e.g., temperature, oxygenation, nutrient supply) to maximize the activity of this key enzyme, thereby degrading the toxin. No metabolic inhibitors are introduced, relying solely on the inherent capacity and regulation of the microbial enzymes to break down the toxin, demonstrating effective remediation without external pharmacological interference.

graph TD
    A[Contaminated Site] --> B(Introduce/Enhance Microbial Consortium);
    B --> C[Optimize Environmental Conditions (Temp, O2, Nutrients)];
    C --> D[Maximized Toxin Degradation Enzyme Activity];
    D --> E[Effective Toxin Bioremediation (No Inhibitor)];
    E --> F[Clean Environment];

Derivative 61.4: Augmented Reality (AR) Guided Self-Administration

Derivation Axis: Integration with Emerging Tech (AR for Patient Guidance)
Enabling Description: An Augmented Reality (AR) application providing step-by-step guidance for SCD patients self-administering mitapivat (e.g., mitapivat sulfate) as monotherapy, ensuring correct dosage, timing, and storage, in the absence of CYP3A4/5 inhibitors. The AR interface, displayed via smart glasses or a smartphone overlay, projects visual cues directly onto the medication packaging and dispenser. It offers real-time reminders, verifies medication (via QR code scanning), and logs adherence, minimizing errors and promoting consistent self-management, thereby ensuring therapeutic levels without needing to modify metabolism with inhibitors.

graph TD
    A[SCD Patient] --> B(AR Device (Smart Glasses/Smartphone));
    B --> C[AR Overlay: Medication Guidance (Dose, Time, Storage)];
    C --> D[QR Code Scan (Medication Verification)];
    D --> E[Logging Adherence Data];
    E --> F[Consistent Mitapivat Self-Administration (No Inhibitor)];
    F --> G[Therapeutic Effect in SCD];

Derivative 61.5: Adaptive Dose Tapering Protocol (Absence of Inhibitors)

Derivation Axis: The "Inverse" or Failure Mode (Controlled Withdrawal/Cessation)
Enabling Description: An adaptive dose tapering protocol for mitapivat (e.g., mitapivat sulfate) in SCD patients, where the drug is gradually reduced and eventually discontinued in the absence of CYP3A4/5 inhibitors. This protocol uses a predictive model that evaluates patient response (e.g., stable hemoglobin, reduced sickling events for >6 months) and tolerability. The "failure mode" here is the intentional, controlled removal of the drug. The tapering schedule (e.g., 25% dose reduction every 4 weeks) is adjusted based on observed clinical parameters, ensuring a safe and effective withdrawal from therapy without the complications of managing inhibitor interactions, which could inadvertently prolong drug action during tapering.

graph TD
    A[SCD Patient (Stable)] --> B(Evaluate Clinical Response for Tapering);
    B --> C[Predictive Tapering Model (No Inhibitor)];
    C --> D[Gradual Mitapivat Dose Reduction];
    D -- Monitor Hb, Sickling, Side Effects --> E[Adaptive Adjustment of Taper Rate];
    E --> F[Successful Mitapivat Discontinuation (Controlled Withdrawal)];

Claim 65 Derivatives: Method of treating Thalassemia with mitapivat and a CYP3A4/5 inducer

Claim 65: A method of treating thalassemia in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof and an effective amount of an inducer of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 65.1: Prophylactic Co-administration with Environmental Toxin Counteraction

Derivation Axis: Operational Parameter Expansion (Prophylactic Use, Stress Response)
Enabling Description: A method of treating thalassemia by co-administering mitapivat (e.g., mitapivat sulfate) with a CYP3A4/5 inducer (e.g., St. John's Wort extract, 300 mg daily) as a prophylactic measure in subjects residing in environments with known exposure to high levels of CYP3A4/5-inducing environmental toxins (e.g., polycyclic aromatic hydrocarbons). The inducer is selected to ensure that any mitapivat administered maintains a consistent and effective clearance rate, preventing unintended accumulation and potential side effects in individuals whose baseline CYP3A4/5 activity might be elevated due to environmental factors. This preemptive induction stabilizes mitapivat exposure, crucial for chronic conditions like thalassemia.

graph TD
    A[Thalassemia Subject (High Environmental Inducer Exposure)] --> B(Prophylactic CYP3A4/5 Inducer (St. John's Wort));
    B --> C[Mitapivat Administration (Dose Adjusted for Induction)];
    C --> D[Stabilized Mitapivat Clearance];
    D --> E[Consistent Therapeutic Effect in Thalassemia (Prophylactic)];

Derivative 65.2: 3D-Printed Bi-Layer Tablet for Separated Release

Derivation Axis: Material & Component Substitution (Manufacturing, Release Profile)
Enabling Description: A method of treating thalassemia using a 3D-printed bi-layer oral tablet. One layer contains mitapivat (e.g., mitapivat sulfate) formulated for immediate release. The second layer contains a CYP3A4/5 inducer (e.g., rifabutin) embedded in a swellable polymer matrix (e.g., polyethylene oxide) designed for delayed and sustained release. This precise spatial and temporal control over drug release, enabled by 3D printing technology, ensures that the inducer begins its action after initial mitapivat absorption, optimizing the metabolic interaction and providing a more tailored pharmacokinetic profile for thalassemia management.

graph TD
    A[3D-Printed Bi-Layer Tablet] --> B(Oral Administration);
    B --> C{Immediate Release Mitapivat Layer};
    C --> D[Mitapivat Absorption];
    B --> E{Delayed/Sustained Release Inducer Layer};
    E --> F[Inducer Release & Absorption];
    D & F --> G[Optimized Metabolic Interaction for Thalassemia];

Derivative 65.3: Cosmetics/Dermatology - Pigment Production Modulator

Derivation Axis: Cross-Domain Application (Cosmetics/Dermatology)
Enabling Description: A method for modulating melanin production in skin for cosmetic purposes (e.g., hyperpigmentation treatment, analogous to thalassemia treatment affecting red blood cell function). A topical skin lightening agent (analogous to mitapivat, e.g., a tyrosinase inhibitor) is applied to the skin. To control its cellular uptake and epidermal persistence, a topical enzyme inducer (analogous to a CYP3A4/5 inducer, e.g., a retinoid derivative that upregulates skin P450s like CYP26A1) is co-applied. This inducer promotes the metabolism of the lightening agent within keratinocytes and melanocytes, allowing for a controlled, localized effect and reducing systemic absorption, crucial for safety and efficacy in cosmetic applications.

graph TD
    A[Skin Area with Hyperpigmentation] --> B(Apply Topical Tyrosinase Inhibitor);
    B --> C(Co-apply Topical Retinoid Inducer);
    C --> D[Inducer Uptake & Skin P450 Upregulation];
    D --> E[Enhanced Metabolism of Tyrosinase Inhibitor];
    E --> F[Controlled Melanin Production Modulation];
    F --> G[Improved Skin Tone / Hyperpigmentation Treatment];

Derivative 65.4: Federated Learning for Inducer-Mitapivat Dose Prediction

Derivation Axis: Integration with Emerging Tech (AI/Federated Learning)
Enabling Description: A federated learning framework used to develop robust AI models for predicting optimal mitapivat (e.g., mitapivat sulfate) and CYP3A4/5 inducer (e.g., rifampin) dosages in thalassemia patients. Patient data from multiple clinical sites (e.g., hospitals, research centers) is used to train a global model collaboratively, without sharing raw patient data, maintaining privacy. The model learns complex relationships between patient demographics, genetic factors, clinical markers, and optimal drug-drug interaction parameters. This allows for highly accurate, personalized dosing recommendations for combined therapy, improving efficacy and safety across diverse thalassemia populations.

graph TD
    A[Clinical Site 1 Data] --> B{Federated Learning Server};
    C[Clinical Site 2 Data] --> B;
    D[Clinical Site N Data] --> B;
    B --> E[Global AI Model Training (Privacy-Preserving)];
    E --> F[Personalized Mitapivat + Inducer Dose Prediction];
    F --> G[Improved Thalassemia Treatment Outcomes];

Derivative 65.5: Mitapivat + Inducer in a "Low-Responsiveness" Patient Population

Derivation Axis: The "Inverse" or Failure Mode (Targeting Low-Responsiveness)
Enabling Description: A method for treating thalassemia in a subpopulation of patients identified as "low-responders" to mitapivat monotherapy (e.g., due to highly active intrinsic CYP3A4/5 or other rapid clearance mechanisms), considered a "failure mode" of standard treatment. In these patients, a higher-than-standard dose of mitapivat (e.g., mitapivat sulfate, 100-200 mg twice daily) is co-administered with a strong CYP3A4/5 inducer (e.g., rifampin, 600 mg daily). The inducer paradoxically is used to further accelerate mitapivat's already rapid clearance, thereby necessitating the higher mitapivat dose. This aggressive approach aims to overcome the "low-responsiveness" by driving a faster metabolic cycle, potentially forcing a higher turnover of erythrocyte populations and a more robust therapeutic effect in these refractory cases.

graph TD
    A[Thalassemia Subject (Low-Responder)] --> B{High Intrinsic CYP3A4/5 Activity};
    B --> C[Administer High Dose Mitapivat];
    C --> D[Co-administer Strong CYP3A4/5 Inducer];
    D --> E[Even Faster Mitapivat Clearance];
    E --> F[Forced High Turnover / Overcome Low-Responsiveness];
    F --> G[Therapeutic Effect in Refractory Thalassemia];

Claim 74 Derivatives: Method of treating Thalassemia with mitapivat in the absence of a CYP3A4/5 inducer

Claim 74: A method of treating thalassemia in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof in the absence of an inducer of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 74.1: Mitapivat Micro-Needle Array for Controlled Release

Derivation Axis: Material & Component Substitution (Novel Delivery System)
Enabling Description: A method of treating thalassemia by administering mitapivat (e.g., mitapivat sulfate) via a dissolvable micro-needle array patch applied to the skin. The micro-needles, fabricated from biocompatible polymers (e.g., hyaluronic acid, polyvinyl alcohol) encapsulating mitapivat, penetrate the stratum corneum and dissolve, delivering the drug directly into the systemic circulation. This bypasses first-pass hepatic metabolism, ensuring predictable bioavailability and consistent drug levels in the absence of CYP3A4/5 inducers. The dose is pre-loaded into the micro-needle array for precise, controlled release over several hours.

graph TD
    A[Mitapivat Micro-Needle Array Patch] --> B(Apply to Skin);
    B --> C[Micro-Needles Penetrate Stratum Corneum];
    C --> D[Dissolution of Micro-Needles];
    D --> E[Direct Mitapivat Delivery to Capillaries];
    E --> F[Systemic Absorption (Bypasses First-Pass)];
    F --> G[Predictable Mitapivat Levels (No Inducer) for Thalassemia];

Derivative 74.2: Dose Adjustment Based on Ethnic-Specific CYP3A4/5 Activity

Derivation Axis: Operational Parameter Expansion (Ethnic Stratification)
Enabling Description: A method of treating thalassemia using mitapivat (e.g., mitapivat sulfate) in the absence of CYP3A4/5 inducers, where the initial dose and subsequent adjustments are based on the subject's ethnic background, which is known to correlate with CYP3A4/5 genetic polymorphisms and activity. For example, populations with generally lower average CYP3A4/5 activity would receive a lower initial mitapivat dose (e.g., 20 mg daily), while those with higher activity might receive a standard dose (e.g., 50 mg daily). This population-level pharmacokinetic adjustment minimizes trial-and-error dosing and optimizes efficacy without active metabolic modulation.

graph TD
    A[Thalassemia Subject] --> B(Determine Ethnic Background);
    B --> C{Estimate Population-Level CYP3A4/5 Activity};
    C --> D[Adjust Initial Mitapivat Dose (No Inducer)];
    D --> E[Administer Mitapivat];
    E --> F[Optimized Therapeutic Effect in Thalassemia];

Derivative 74.3: Smart Agriculture - Nutrient Sensing & Delivery

Derivation Axis: Cross-Domain Application (Smart Agriculture)
Enabling Description: A "smart farming" system for optimizing the absorption and utilization of a critical soil nutrient (analogous to mitapivat, e.g., a specific chelated metal ion) by crops in the absence of enzymatic inducers. Soil IoT sensors continuously monitor nutrient levels, pH, and microbial activity. This data is fed to an AI-controlled irrigation system that delivers the nutrient precisely when plant uptake mechanisms are maximally active, and soil conditions are optimal, leveraging natural plant physiology. No external "inducers" (e.g., chemicals to boost microbial degradation of competitors) are used, relying on the intrinsic plant-soil dynamics to ensure efficient nutrient delivery and healthy crop growth.

graph TD
    A[Agricultural Field] --> B(Soil IoT Sensors);
    B --> C[AI-Controlled Irrigation System];
    C --> D[Precise Nutrient Delivery (Chelated Metal Ion)];
    D --> E[Maximized Plant Uptake (No Inducer)];
    E --> F[Efficient Nutrient Utilization & Crop Growth];

Derivative 74.4: Blockchain-Secured Patient Record for Mitapivat Monotherapy

Derivation Axis: Integration with Emerging Tech (Blockchain for EHR)
Enabling Description: A blockchain-secured electronic health record (EHR) system specifically designed for thalassemia patients receiving mitapivat (e.g., mitapivat sulfate) monotherapy (i.e., in the absence of CYP3A4/5 inducers). Each patient's clinical history, treatment plan, mitapivat dosage, and laboratory results (Hb levels, reticulocyte counts) are recorded as encrypted, timestamped transactions on a distributed ledger. This ensures immutable, auditable, and secure access to critical patient data by authorized healthcare providers, facilitating consistent care and preventing accidental co-administration of contraindicated inducers, enhancing patient safety and data integrity.

graph TD
    A[Thalassemia Patient] --> B(EHR Data (Clinical History, Labs, Mitapivat Dose));
    B --> C[Encrypt & Hash Data];
    C --> D[Add to Blockchain Ledger (Immutable Transaction)];
    D --> E{Authorized Healthcare Providers};
    E --> F[Secure & Auditable Access to Patient Record];
    F --> G[Consistent Mitapivat Monotherapy Management];

Derivative 74.5: Mitapivat with "Delayed Activation" for Gentle Onset

Derivation Axis: The "Inverse" or Failure Mode (Controlled Onset/Reduced Potency)
Enabling Description: A mitapivat (e.g., mitapivat sulfate) formulation designed for a "delayed activation" profile, providing a gentle onset of therapeutic action. This is achieved through a prodrug form of mitapivat that requires slow, non-enzymatic hydrolysis in the systemic circulation to release the active compound, rather than relying on rapid enzymatic cleavage or modulation by CYP3A4/5 inducers. This inherently slow release profile, in the absence of inducers, mitigates potential initial adverse events or patient intolerance, offering a "low-power" or "limited-functionality" start to therapy, ensuring patient comfort during initiation.

graph TD
    A[Mitapivat Prodrug (Slow Hydrolysis)] --> B(Oral Administration);
    B --> C[Systemic Circulation];
    C --> D[Slow Non-Enzymatic Hydrolysis];
    D --> E[Gradual Release of Active Mitapivat];
    E --> F[Gentle Onset of Therapeutic Effect (Delayed Activation)];
    F --> G[Thalassemia Treatment with Minimized Initial Side Effects];

Claim 80 Derivatives: Method of treating Thalassemia with mitapivat and a CYP3A4/5 inhibitor

Claim 80: A method of treating thalassemia in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof and an effective amount of an inhibitor of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 80.1: Dose Sparing with High-Affinity Allosteric Inhibitor

Derivation Axis: Operational Parameter Expansion (Dose Sparing, Potency Enhancement)
Enabling Description: A method of treating thalassemia by administering a significantly reduced dose of mitapivat (e.g., mitapivat sulfate, 5-20 mg daily) in combination with a novel, high-affinity allosteric CYP3A4 inhibitor. This inhibitor (e.g., a non-azole small molecule developed to specifically bind to a site distinct from the active site, inducing a conformational change that reduces substrate binding) provides a potent and selective inhibition of CYP3A4, allowing for a 5-10 fold reduction in the mitapivat dose while maintaining therapeutic exposure. This "dose sparing" strategy minimizes mitapivat-related side effects, particularly important for long-term thalassemia management.

graph TD
    A[Thalassemia Subject] --> B(Administer High-Affinity Allosteric CYP3A4 Inhibitor);
    B --> C[Conformational Change in CYP3A4 (Reduced Activity)];
    C --> D[Reduced Mitapivat Metabolism];
    D --> E[Administer Significantly Reduced Mitapivat Dose];
    E --> F[Equivalent Mitapivat Exposure (Dose Sparing)];
    F --> G[Therapeutic Effect in Thalassemia with Minimized Side Effects];

Derivative 80.2: Implants for Sustained Co-Delivery of Mitapivat and Inhibitor

Derivation Axis: Material & Component Substitution (Implantable Device)
Enabling Description: A method of treating thalassemia by implanting a biodegradable, subcutaneous polymeric device that provides sustained, co-delivery of mitapivat (e.g., mitapivat free base) and a moderate CYP3A4/5 inhibitor (e.g., a slow-release formulation of erythromycin). The implant, made of poly(lactic-co-glycolic acid) (PLGA) with individually loaded drug compartments, releases both compounds at a controlled rate over several months (e.g., 3-6 months). This ensures continuous and stable plasma concentrations of both drugs, optimizing the drug-drug interaction for consistent mitapivat exposure without daily oral dosing, enhancing patient compliance and long-term therapeutic management.

graph TD
    A[Thalassemia Subject] --> B(Subcutaneous Implant Procedure);
    B --> C[Biodegradable Polymeric Implant (Mitapivat + Inhibitor)];
    C --> D[Sustained Co-Release of Mitapivat & Erythromycin];
    D --> E[Continuous & Stable Plasma Levels];
    E --> F[Optimized Mitapivat Exposure for Thalassemia];

Derivative 80.3: Precision Viticulture - Flavor Compound Modulation

Derivation Axis: Cross-Domain Application (Viticulture/Food Science)
Enabling Description: A method for modulating the concentration of specific flavor precursors (analogous to mitapivat) in grapevines to enhance wine aromatic profiles, by applying a plant enzyme inhibitor (analogous to CYP3A4/5 inhibitor) to the plant foliage or roots. The flavor precursors are naturally produced in the grape. The inhibitor, e.g., a specific fungicide or herbicide that also acts as an enzyme inhibitor, reduces the activity of plant enzymes (e.g., glycosyltransferases or phenol oxidases) responsible for the degradation or conjugation of these flavor precursors. This leads to a higher concentration of free, active flavor compounds in the ripe grapes, improving the sensory quality of the resulting wine.

graph TD
    A[Grapevine] --> B(Natural Flavor Precursor Production);
    C[Apply Plant Enzyme Inhibitor (e.g., Specific Fungicide)];
    C --> D[Inhibition of Degradation Enzymes];
    D --> E[Increased Free Flavor Precursor Concentration];
    E --> F[Enhanced Wine Aromatic Profile (Viticulture)];

Derivative 80.4: Digital Biomarker Monitoring & Feedback for Inhibitor-Co-Therapy

Derivation Axis: Integration with Emerging Tech (Digital Biomarkers, AI Feedback)
Enabling Description: A digital health platform for thalassemia patients on mitapivat (e.g., mitapivat sulfate) and a CYP3A4/5 inhibitor. The platform integrates continuous glucose monitoring (CGM, adapted for real-time lactate levels, an indirect biomarker for erythrocyte metabolism) and wearable activity trackers. An AI system analyzes this continuous digital biomarker data, identifying deviations from a personalized baseline. It then provides real-time feedback to the patient and clinician, suggesting adjustments to the CYP3A4/5 inhibitor dose (e.g., itraconazole) to maintain optimal mitapivat efficacy and prevent metabolic imbalances associated with thalassemia.

graph TD
    A[Thalassemia Patient] --> B(Wearable Activity Tracker);
    B --> C(CGM for Lactate Levels);
    C --> D{Digital Health Platform};
    D --> E[AI Biomarker Analysis];
    E --> F{Real-time Feedback: Inhibitor Dose Adjustment};
    F --> G[Optimized Thalassemia Treatment & Metabolic Balance];

Derivative 80.5: Mitapivat + Inhibitor for "Intermittent Treatment" Regimen

Derivation Axis: The "Inverse" or Failure Mode (Intermittent Functionality)
Enabling Description: A method for treating thalassemia using an "intermittent treatment" regimen of mitapivat (e.g., mitapivat sulfate) and a CYP3A4/5 inhibitor (e.g., clarithromycin). This regimen involves administering the combination for a defined period (e.g., 2 weeks on, 1 week off) to allow for periods of drug holiday. During the "off" periods, the reduced mitapivat exposure (a temporary "failure" of continuous therapeutic levels) allows the patient's system to normalize and potentially reduces drug accumulation and long-term toxicity. The inhibitor is crucial during the "on" periods to rapidly achieve and maintain therapeutic mitapivat levels during the shorter treatment windows, optimizing the "intermittent functionality" of the therapy.

graph TD
    A[Thalassemia Subject] --> B{Treatment Cycle (e.g., 2 weeks On, 1 week Off)};
    B -- "On" Period --> C[Mitapivat + CYP3A4/5 Inhibitor (Clarithromycin)];
    C --> D[Achieve Rapid Therapeutic Levels];
    B -- "Off" Period --> E[Drug Holiday (Reduced Exposure)];
    E --> F[System Normalization / Reduced Accumulation];
    F -- Cycle Restart --> C;
    D & F --> G[Optimized Intermittent Thalassemia Treatment];

Claim 89 Derivatives: Method of treating Thalassemia with mitapivat in the absence of a CYP3A4/5 inhibitor

Claim 89: A method of treating thalassemia in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof in the absence of an inhibitor of cytochrome P450 3A4 (CYP3A4) or 3A5 (CYP3A5).

Derivative 89.1: Targeted Gene Therapy for PKLR Upregulation

Derivation Axis: Operational Parameter Expansion (Gene Therapy, Endogenous Production)
Enabling Description: A method of treating thalassemia by administering mitapivat (e.g., mitapivat sulfate) in the absence of CYP3A4/5 inhibitors, concurrently with a gene therapy aimed at increasing endogenous pyruvate kinase R (PKR) expression in erythroid cells. An adeno-associated viral (AAV) vector delivers a functional copy of the PKLR gene or a gene-editing tool to upregulate its expression. By increasing the target enzyme (PKR) levels, the need for high exogenous mitapivat concentrations is reduced, and its therapeutic effect is amplified without requiring pharmacological inhibition of its metabolism.

graph TD
    A[Thalassemia Subject] --> B(AAV Gene Therapy: PKLR Upregulation);
    B --> C[Increased Endogenous PKR Expression];
    C --> D[Administer Mitapivat (Reduced Dose, No Inhibitor)];
    D --> E[Amplified PKR Activation & Hemoglobin Production];
    E --> F[Therapeutic Effect in Thalassemia];

Derivative 89.2: Sublingual Film for Rapid Absorption

Derivation Axis: Material & Component Substitution (Alternative Delivery Route)
Enabling Description: A method of treating thalassemia by administering mitapivat (e.g., mitapivat sulfate) as a fast-dissolving sublingual film. This delivery route bypasses first-pass hepatic metabolism entirely, allowing for rapid and direct systemic absorption into the bloodstream. By avoiding the liver, where CYP3A4/5 enzymes are highly prevalent, predictable and consistent mitapivat exposure is achieved in the absence of CYP3A4/5 inhibitors. The film is composed of hydrophilic polymers (e.g., pullulan, hydroxypropyl cellulose) and disintegrants for quick dissolution.

graph TD
    A[Mitapivat Sublingual Film] --> B(Placement under Tongue);
    B --> C[Rapid Dissolution & Permeation];
    C --> D[Direct Systemic Absorption (Bypasses Liver)];
    D --> E[Consistent Mitapivat Plasma Levels (No Inhibitor)];
    E --> F[Therapeutic Effect in Thalassemia];

Derivative 89.3: Smart Water Management - Algae Nutrient Control

Derivation Axis: Cross-Domain Application (Environmental Science/Water Treatment)
Enabling Description: A method for controlling unwanted algal growth in water bodies (e.g., reservoirs, ponds) by precisely managing nutrient levels (analogous to mitapivat's role in cell function) without introducing any metabolic inhibitors. Automated water quality sensors continuously monitor phosphate, nitrate, and silicate concentrations. An AI-driven system then controls the inflow of nutrient-rich water or introduces nutrient-sequestering agents to maintain levels below the threshold required for problematic algal species. This relies on the natural metabolic limits of the algae, where they "fail" to thrive due to nutrient scarcity, rather than using external enzymatic inhibition of a treatment agent.

graph TD
    A[Water Body] --> B(Automated Water Quality Sensors);
    B --> C[AI-Driven Nutrient Control System];
    C --> D[Adjust Nutrient Inflow / Introduce Sequestering Agents];
    D --> E[Nutrient Levels Below Algal Growth Threshold];
    E --> F[Algal Growth Control (No Inhibitor) / Environmental Balance];

Derivative 89.4: AI-Assisted Patient Screening for Monotherapy Suitability

Derivation Axis: Integration with Emerging Tech (AI for Patient Selection)
Enabling Description: An AI-powered patient screening tool that identifies thalassemia subjects most suitable for mitapivat (e.g., mitapivat sulfate) monotherapy (i.e., in the absence of CYP3A4/5 inhibitors). The AI analyzes a vast dataset of patient characteristics, including genetic markers (beyond CYP3A4/5), co-morbidities, and baseline hematological parameters. It predicts patients likely to achieve optimal therapeutic response without needing metabolic modulation, minimizing unnecessary drug exposures and simplifying treatment regimens for eligible individuals.

graph TD
    A[Thalassemia Patient Data] --> B(AI Screening Tool);
    B --> C[Analyze Genetic, Clinical, Hematological Markers];
    C --> D[Predict Monotherapy Response (No Inhibitor)];
    D --> E{Patient Suitability for Mitapivat Monotherapy};
    E --> F[Personalized Treatment Pathway];

Derivative 89.5: Mitapivat "Run-Out" Phase for Gradual Withdrawal

Derivation Axis: The "Inverse" or Failure Mode (Controlled Cessation)
Enabling Description: A "run-out" phase protocol for thalassemia patients discontinuing mitapivat (e.g., mitapivat sulfate) therapy in the absence of CYP3A4/5 inhibitors. After the main treatment, a final, fixed low dose of mitapivat (e.g., 5-10 mg daily) is administered for a short, predefined period (e.g., 7-14 days). This allows the drug to gradually clear from the system through natural metabolic processes without abrupt cessation, mitigating potential rebound effects or withdrawal symptoms. The absence of inhibitors ensures that the natural clearance rate defines the "run-out" profile, preventing unintended prolongation of drug action.

graph TD
    A[Thalassemia Subject (Discontinuing Mitapivat)] --> B(Enter Mitapivat "Run-Out" Phase);
    B --> C[Administer Fixed Low Dose Mitapivat (No Inhibitor)];
    C --> D[Natural Mitapivat Clearance];
    D --> E[Gradual Withdrawal & System Adjustment];
    E --> F[Minimizing Rebound Effects / Withdrawal Symptoms];

Claim 95 Derivatives: Method of treating PKD with mitapivat and a p-glycoprotein inhibitor

Claim 95: A method of treating pyruvate kinase deficiency (PKD) in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof and an effective amount of a p-glycoprotein inhibitor.

Derivative 95.1: P-gp Inhibition for Enhanced Intracellular Mitapivat Accumulation

Derivation Axis: Operational Parameter Expansion (Targeted Accumulation)
Enabling Description: A method of treating PKD where a strong p-glycoprotein (P-gp) inhibitor (e.g., tariquidar, 10 mg daily) is co-administered with mitapivat (e.g., mitapivat sulfate, 20-50 mg twice daily). The P-gp inhibitor is specifically used to enhance the intracellular accumulation of mitapivat within erythrocytes, overcoming potential efflux pump activity that might limit its effective concentration at the PKR target site. This leads to a higher local concentration of mitapivat inside red blood cells, thus amplifying the therapeutic effect on PKR activation and reducing the overall systemic dose required.

graph TD
    A[PKD Subject] --> B(Administer Strong P-gp Inhibitor (Tariquidar));
    B --> C[Inhibition of P-gp Efflux Pumps on RBCs];
    C --> D[Administer Mitapivat];
    D --> E[Enhanced Intracellular Mitapivat Accumulation];
    E --> F[Amplified PKR Activation in RBCs];
    F --> G[Therapeutic Effect in PKD];

Derivative 95.2: Co-Formulated Nano-Suspension with P-gp Inhibitor

Derivation Axis: Material & Component Substitution (Nanotechnology, Co-Formulation)
Enabling Description: A method of treating PKD by orally administering a co-formulated nano-suspension of mitapivat (e.g., mitapivat free base) and a P-gp inhibitor (e.g., cyclosporine). The drugs are micronized and stabilized in a colloidal suspension with surfactants and polymers (e.g., poloxamer, hypromellose), improving their dissolution rate and particle size for enhanced absorption. The P-gp inhibitor in the nano-suspension specifically targets intestinal P-gp, maximizing mitapivat absorption and bioavailability, crucial for consistent drug levels and therapeutic efficacy in PKD.

graph TD
    A[Mitapivat + P-gp Inhibitor] --> B(Nano-Suspension Formulation);
    B --> C(Oral Administration);
    C --> D[Enhanced Dissolution & Absorption];
    D --> E[Inhibition of Intestinal P-gp];
    E --> F[Increased Mitapivat Bioavailability];
    F --> G[Therapeutic Effect in PKD];

Derivative 95.3: Pest Control - Pesticide Potency Enhancement

Derivation Axis: Cross-Domain Application (Agri-Pest Control)
Enabling Description: A method for enhancing the efficacy of a systemic pesticide (analogous to mitapivat) in agriculture by co-applying a P-glycoprotein-like efflux pump inhibitor (analogous to P-gp inhibitor) to target insect pests. The pesticide, a novel neonicotinoid, is applied as a spray. The co-applied inhibitor, a synthetic pyrethroid synergist, specifically blocks the efflux pumps (e.g., ABC transporters) in insect gut cells, increasing the intracellular concentration and systemic distribution of the neonicotinoid. This allows for lower pesticide doses, reducing environmental impact while maintaining potent pest control.

graph TD
    A[Insect Pest] --> B(Apply Neonicotinoid Pesticide);
    C[Co-apply Efflux Pump Inhibitor];
    C --> D[Inhibition of Insect Efflux Pumps];
    D --> E[Increased Intracellular Pesticide Concentration];
    E --> F[Enhanced Pesticide Potency & Pest Control];

Derivative 95.4: IoT-Enabled Smart Pill for Adherence & P-gp Inhibition

Derivation Axis: Integration with Emerging Tech (IoT, Smart Pills)
Enabling Description: A smart pill containing mitapivat (e.g., mitapivat sulfate) and a P-gp inhibitor (e.g., quinidine). The pill is equipped with an ingestible sensor that communicates with an external receiver (e.g., smartphone app) upon dissolution, confirming ingestion. This IoT-enabled system monitors patient adherence to the combined therapy, critical for ensuring consistent P-gp inhibition and optimal mitapivat bioavailability in PKD treatment. The app can also provide reminders and educational content, linking adherence directly to therapeutic outcomes.

graph TD
    A[PKD Subject] --> B(Ingest Smart Pill (Mitapivat + P-gp Inhibitor));
    B --> C[Ingestible Sensor Activation];
    C --> D[Data Transmission to Smartphone App];
    D --> E[Adherence Monitoring & Reminders];
    E --> F[Consistent P-gp Inhibition & Mitapivat Bioavailability];
    F --> G[Therapeutic Effect in PKD];

Derivative 95.5: Reduced Mitapivat Dose with P-gp Inhibitor for Hepatic Impairment

Derivation Axis: The "Inverse" or Failure Mode (Limited Functionality for Specific Population)
Enabling Description: A modified treatment regimen for PKD patients with hepatic impairment (a "failure" of normal drug metabolism), where mitapivat (e.g., mitapivat sulfate) clearance is already compromised. In such cases, a significantly reduced mitapivat dose (e.g., 50% or more reduction from standard) is co-administered with a mild P-gp inhibitor (e.g., a low dose of captopril). The P-gp inhibitor is used not to dramatically increase mitapivat levels, but to provide a subtle, predictable boost to its systemic exposure, ensuring a therapeutic effect with a minimal mitapivat load, thereby minimizing further stress on the impaired liver. This represents a "limited-functionality" application of the inhibitor to compensate for a failing metabolic system.

graph TD
    A[PKD Patient with Hepatic Impairment] --> B(Reduced Mitapivat Dose);
    B --> C(Co-administer Mild P-gp Inhibitor (Captopril));
    C --> D[Subtle Boost to Mitapivat Exposure];
    D --> E[Therapeutic Effect with Minimized Hepatic Burden];
    E --> F[Close Monitoring of Liver Function & Drug Levels];

Claim 102 Derivatives: Method of treating PKD with mitapivat in the absence of a p-glycoprotein inhibitor

Claim 102: A method of treating pyruvate kinase deficiency (PKD) in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof in the absence of a p-glycoprotein inhibitor.

Derivative 102.1: Mitapivat with Enhanced Intestinal Permeability Excipients

Derivation Axis: Material & Component Substitution (Excipients, Permeability Enhancers)
Enabling Description: A method of treating PKD by administering mitapivat (e.g., mitapivat sulfate) formulated with intestinal permeability enhancers, such as medium-chain fatty acids (e.g., sodium caprate) or chitosan derivatives, in the absence of P-gp inhibitors. These excipients transiently open tight junctions in the intestinal epithelium, increasing paracellular transport of mitapivat and improving its overall absorption and bioavailability. This strategy overcomes potential P-gp efflux limitations endogenously without introducing an additional pharmacological agent.

graph TD
    A[Mitapivat + Permeability Enhancers] --> B(Oral Administration);
    B --> C{Intestinal Epithelium};
    C --> D[Transient Tight Junction Opening];
    D --> E[Increased Paracellular Mitapivat Transport];
    E --> F[Enhanced Mitapivat Absorption (No P-gp Inhibitor)];
    F --> G[Therapeutic Effect in PKD];

Derivative 102.2: Ultra-High Dose Mitapivat for P-gp Saturation

Derivation Axis: Operational Parameter Expansion (Extreme Dose, Saturation Kinetics)
Enabling Description: A method of treating PKD in a subject by administering an ultra-high daily dose of mitapivat (e.g., mitapivat sulfate, 500-1000 mg daily), deliberately chosen to saturate intestinal P-gp efflux pumps, thereby effectively increasing the net absorption of mitapivat without co-administering a P-gp inhibitor. This approach relies on concentration-dependent saturation kinetics of the transporter, ensuring sufficient systemic exposure by overwhelming the efflux mechanism. Doses are carefully monitored for safety and efficacy.

graph TD
    A[PKD Subject] --> B(Administer Ultra-High Mitapivat Dose);
    B --> C[Saturate Intestinal P-gp Efflux Pumps];
    C --> D[Increased Net Mitapivat Absorption];
    D --> E[High Systemic Mitapivat Exposure (No P-gp Inhibitor)];
    E --> F[Therapeutic Effect in PKD];

Derivative 102.3: Wastewater Treatment - Biofilm-Mediated Toxin Uptake

Derivation Axis: Cross-Domain Application (Environmental Engineering/Wastewater)
Enabling Description: A method for removing specific persistent organic pollutants (POPs, analogous to mitapivat) from wastewater using engineered microbial biofilms, in the absence of any efflux pump inhibitors. The biofilm-forming microorganisms are selected for their high intrinsic capacity to actively take up and sequester POPs from the aqueous phase. The treatment system relies on optimizing biofilm growth and density within a bioreactor, leveraging the natural uptake mechanisms of the microorganisms to achieve effective pollutant removal without chemical inhibitors to boost uptake.

graph TD
    A[Wastewater with POPs] --> B(Biofilm Bioreactor);
    B --> C[Microbial Biofilm Growth];
    C --> D[Active Uptake & Sequestration of POPs (No Efflux Inhibitor)];
    D --> E[Pollutant Removal from Wastewater];
    E --> F[Treated Water];

Derivative 102.4: Wearable Sensor for Metabolic Biomarkers

Derivation Axis: Integration with Emerging Tech (IoT Sensors, Biomarker Monitoring)
Enabling Description: A wearable, non-invasive sensor system for PKD patients receiving mitapivat (e.g., mitapivat sulfate) in the absence of P-gp inhibitors. The sensor continuously monitors metabolic biomarkers (e.g., skin temperature, heart rate variability, sweat metabolites like lactate) that correlate with red blood cell energy status and hemolytic activity. An embedded algorithm analyzes these trends, identifying changes that indicate suboptimal mitapivat exposure or efficacy, allowing for proactive dose adjustments without needing to modify drug transport via P-gp inhibition.

graph TD
    A[PKD Subject] --> B(Wearable Non-Invasive Sensor);
    B --> C[Continuous Monitoring: Skin Temp, HRV, Sweat Metabolites];
    C --> D[Embedded Algorithm: Correlate with RBC Status];
    D --> E[Detect Suboptimal Mitapivat Efficacy (No P-gp Inhibitor)];
    E --> F[Proactive Mitapivat Dose Adjustment];

Derivative 102.5: Mitapivat with "Delayed Release to Bypass P-gp Rich Regions"

Derivation Axis: The "Inverse" or Failure Mode (Bypassing Efflux)
Enabling Description: A mitapivat (e.g., mitapivat sulfate) formulation designed for delayed, colon-targeted release. The tablet is coated with a pH-sensitive polymer (e.g., Eudragit® S) that resists dissolution until the colon (pH > 7.0). This strategy aims to bypass the duodenum and jejunum, which are regions known to have high concentrations of P-gp, thereby reducing the impact of P-gp efflux on mitapivat absorption. By delivering the drug to a region with lower P-gp expression, it effectively mitigates the "failure" of P-gp mediated efflux without using a P-gp inhibitor, ensuring sufficient systemic exposure.

graph TD
    A[Mitapivat Colon-Targeted Tablet] --> B(Oral Administration);
    B --> C{Upper GI Tract (P-gp Rich)};
    C -- Tablet Intact --> D{Colon (Lower P-gp Expression)};
    D --> E[Delayed Release & Absorption];
    E --> F[Increased Mitapivat Bioavailability (Bypasses Efflux)];
    F --> G[Therapeutic Effect in PKD];

Claim 108 Derivatives: Method of treating SCD with mitapivat and a p-glycoprotein inhibitor

Claim 108: A method of treating sickle cell disease in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof and an effective amount of a p-glycoprotein inhibitor.

Derivative 108.1: Genetic Profiling for P-gp Genotype-Guided Inhibition

Derivation Axis: Operational Parameter Expansion (Genetic Tailoring, P-gp Genotyping)
Enabling Description: A method of treating SCD where subjects undergo genotyping for P-gp efflux pump polymorphisms (e.g., ABCB1 C3435T, G2677T/A). Based on the genotype, a personalized P-gp inhibitor dosing strategy is implemented. For "super-expresser" P-gp genotypes, a higher dose of a potent P-gp inhibitor (e.g., valspodar, 10-20 mg daily) is co-administered with mitapivat (e.g., mitapivat sulfate, 50-100 mg twice daily) to effectively overcome robust efflux and maximize intracellular mitapivat concentrations in red blood cells. This ensures optimal therapeutic levels for SCD.

graph TD
    A[SCD Subject] --> B(P-gp Genotyping (ABCB1 Polymorphisms));
    B --> C{Super-Expresser Genotype Identified};
    C --> D[Personalized High-Dose P-gp Inhibitor (Valspodar)];
    D --> E[Co-administer Mitapivat];
    E --> F[Maximized Intracellular Mitapivat (Overcome Efflux)];
    F --> G[Therapeutic Effect in SCD];

Derivative 108.2: Bioadhesive Oral Film for Localized Intestinal P-gp Inhibition

Derivation Axis: Material & Component Substitution (Localized Delivery, Bioadhesive)
Enabling Description: A method of treating SCD by administering mitapivat (e.g., mitapivat sulfate) orally, along with a bioadhesive oral film containing a P-gp inhibitor (e.g., verapamil). The film is designed to adhere to the intestinal mucosa, providing a high local concentration of the P-gp inhibitor at the primary site of efflux, thereby maximizing mitapivat absorption without high systemic exposure to the inhibitor. This localized inhibition minimizes systemic side effects of the P-gp inhibitor while optimizing mitapivat bioavailability for SCD treatment.

graph TD
    A[Mitapivat Oral Administration] --> B(Co-administer Bioadhesive Oral Film with P-gp Inhibitor);
    B --> C[Film Adheres to Intestinal Mucosa];
    C --> D[Localized High Concentration of P-gp Inhibitor];
    D --> E[Maximized Intestinal Mitapivat Absorption];
    E --> F[Optimized Mitapivat Bioavailability & Therapeutic Effect in SCD];

Derivative 108.3: Soil Remediation - Enhanced Heavy Metal Uptake in Plants

Derivation Axis: Cross-Domain Application (Environmental Remediation/Phytoremediation)
Enabling Description: A method for phytoremediation of heavy metal contaminated soils using hyperaccumulator plants, where the uptake of heavy metals (analogous to mitapivat) by plant roots is enhanced by co-applying a plant efflux pump inhibitor (analogous to a P-gp inhibitor, e.g., a specific chelating agent that blocks membrane transporters). The inhibitor, applied to the soil, increases the intracellular accumulation of heavy metals within root cells, improving their translocation into the shoots for subsequent harvesting and removal. This strategy boosts the efficiency of phytoremediation, particularly for metals that are naturally effluxed by the plant.

graph TD
    A[Heavy Metal Contaminated Soil] --> B(Plant Hyperaccumulator Seeds);
    C[Co-apply Plant Efflux Pump Inhibitor (Chelating Agent)];
    C --> D[Inhibition of Root Efflux Pumps];
    D --> E[Increased Intracellular Heavy Metal Accumulation in Roots];
    E --> F[Enhanced Translocation to Shoots & Remediation];

Derivative 108.4: Real-time Blood Viscosity Monitoring with Inhibitor Adjustment

Derivation Axis: Integration with Emerging Tech (IoT Sensors, Hemorheology)
Enabling Description: An IoT-enabled system for SCD patients receiving mitapivat (e.g., mitapivat sulfate) and a P-gp inhibitor. A continuous, non-invasive blood viscosity monitor (e.g., a microfluidic chip integrated into a wearable device) provides real-time data on blood rheology, a critical parameter in SCD. This data, correlated with mitapivat plasma levels (via a minimally invasive sensor), is analyzed by an AI algorithm. The AI recommends adaptive adjustments to the P-gp inhibitor dose (e.g., a low dose of amiodarone) to maintain optimal mitapivat exposure, thereby directly impacting blood viscosity and reducing the risk of vaso-occlusive events.

graph TD
    A[SCD Patient] --> B(Non-Invasive Blood Viscosity Monitor);
    B --> C(Minimally Invasive Mitapivat Sensor);
    C --> D{IoT Platform};
    D --> E[AI Analysis: Viscosity & Mitapivat Levels];
    E --> F{Adaptive P-gp Inhibitor Dose Recommendation};
    F --> G[Improved Blood Rheology & SCD Management];

Derivative 108.5: Reduced Mitapivat Efficacy for Diagnostic Challenge

Derivation Axis: The "Inverse" or Failure Mode (Reduced Efficacy for Diagnostic Purpose)
Enabling Description: A method involving the intentional, temporary reduction of mitapivat (e.g., mitapivat sulfate) efficacy by co-administering a strong P-gp inhibitor (e.g., cyclosporine) at a dose designed to over-potentiate mitapivat, leading to a temporary "failure" in its targeted therapeutic window (i.e., higher than optimal exposure). This is used as a diagnostic challenge in SCD patients to identify underlying sensitivities or unexpected pharmacokinetic responses to mitapivat. By observing how the patient's system reacts to transiently supra-therapeutic mitapivat levels, clinicians can better understand individual patient pharmacokinetics and optimize future dosing strategies, effectively using a controlled "overdose" to gain diagnostic insight.

graph TD
    A[SCD Patient (Diagnostic)] --> B(Administer Mitapivat);
    B --> C(Co-administer Over-Potentiating P-gp Inhibitor (Cyclosporine));
    C --> D[Temporarily Supra-therapeutic Mitapivat Levels];
    D --> E[Monitor Patient Response & Pharmacokinetics];
    E --> F[Diagnostic Insight into Mitapivat Sensitivity];
    F --> G[Optimize Future SCD Dosing];

Claim 113 Derivatives: Method of treating SCD with mitapivat in the absence of a p-glycoprotein inhibitor

Claim 113: A method of treating sickle cell disease in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof in the absence of a p-glycoprotein inhibitor.

Derivative 113.1: Mitapivat with Enteric-Coated Multiparticulate System

Derivation Axis: Material & Component Substitution (Formulation, Release Profile)
Enabling Description: A method of treating SCD by administering mitapivat (e.g., mitapivat sulfate) as an enteric-coated multiparticulate system (e.g., pellets or mini-tablets within a capsule). Each micro-unit is coated to protect mitapivat from gastric degradation and ensure targeted release in the small intestine. This controlled release profile optimizes absorption in specific intestinal segments where P-gp expression might be lower or less active, effectively bypassing P-gp rich regions without the need for a P-gp inhibitor, ensuring consistent and enhanced bioavailability for SCD therapy.

graph TD
    A[Mitapivat Enteric-Coated Multiparticulates] --> B(Oral Capsule Administration);
    B --> C{Stomach (Acidic)};
    C -- Coating Intact --> D{Small Intestine (Targeted Release)};
    D --> E[Mitapivat Absorption (Bypasses P-gp Rich Regions)];
    E --> F[Consistent Mitapivat Bioavailability (No P-gp Inhibitor)];
    F --> G[Therapeutic Effect in SCD];

Derivative 113.2: Dosing Based on Dietary P-gp Modulator Intake

Derivation Axis: Operational Parameter Expansion (Lifestyle Factors, Dietary Adjustment)
Enabling Description: A method of treating SCD with mitapivat (e.g., mitapivat sulfate) in the absence of prescribed P-gp inhibitors, where the mitapivat dose is adjusted based on a subject's documented dietary intake of natural P-gp inhibitors (e.g., grapefruit juice, quercetin-rich foods). For subjects with high dietary P-gp inhibitor intake, a reduced mitapivat dose (e.g., 20-50 mg daily) is prescribed to avoid over-exposure. Conversely, for subjects with minimal dietary P-gp modulators, a standard or slightly increased dose (e.g., 50-100 mg daily) ensures therapeutic levels. This integrates lifestyle factors into dosing decisions, treating dietary components as intrinsic modulators.

graph TD
    A[SCD Subject] --> B(Dietary Assessment: Natural P-gp Modulators);
    B --> C{High Dietary Inhibitor Intake / Low Intake};
    C -- High Intake --> D[Reduced Mitapivat Dose (No Prescribed Inhibitor)];
    C -- Low Intake --> E[Standard/Increased Mitapivat Dose (No Prescribed Inhibitor)];
    D & E --> F[Optimized Mitapivat Exposure for SCD];

Derivative 113.3: Space Exploration - Closed-Loop Nutrient Recycling

Derivation Axis: Cross-Domain Application (Space Exploration/Life Support)
Enabling Description: A closed-loop bioregenerative life support system for long-duration space missions, optimizing the uptake of essential nutrients (analogous to mitapivat, e.g., specific amino acids) by crew members from recycled waste streams. The system integrates microbial bioreactors and hydroponic plant growth chambers. The "absence of a P-gp inhibitor" translates to relying solely on the natural absorption and transport mechanisms of human physiology for nutrient uptake, without chemical interventions to boost bioavailability. The system is designed to produce bioavailable forms of nutrients that readily cross membranes without requiring efflux pump inhibition, ensuring crew health in resource-limited environments.

graph TD
    A[Crew Member] --> B(Ingest Recycled Nutrients);
    B --> C[Natural Gastrointestinal Absorption (No Efflux Inhibitor)];
    C --> D[Nutrient Utilization for Health];
    E[Waste Stream] --> F(Bioreactors & Hydroponics);
    F --> B;
    D --> G[Sustained Crew Health in Space];

Derivative 113.4: Decentralized Clinical Trials with Remote PK/PD Modeling

Derivation Axis: Integration with Emerging Tech (Decentralized Clinical Trials)
Enabling Description: A decentralized clinical trial (DCT) platform for SCD patients receiving mitapivat (e.g., mitapivat sulfate) monotherapy (i.e., without P-gp inhibitors). Patients collect blood samples remotely (e.g., microsampling devices) and ship them to a central lab. Remote monitoring devices track adherence and adverse events. An AI-powered PK/PD model, accessible via the DCT platform, analyzes these data points to optimize individual mitapivat dosing. This approach facilitates wider patient recruitment, reduces burden on patients, and enables precise dose adjustments in the absence of P-gp inhibition, directly impacting drug exposure and efficacy.

graph TD
    A[SCD Patient Home] --> B(Microsampling Device for PK);
    B --> C(Remote Monitoring Devices (Adherence, AE));
    C --> D{DCT Platform (Data Aggregation)};
    D --> E[AI PK/PD Model];
    E --> F{Optimized Mitapivat Dose Recommendation (No P-gp Inhibitor)};
    F --> G[Telehealth Physician Review];
    G --> A;

Derivative 113.5: "Minimal Effective Dose" Mitapivat Monotherapy

Derivation Axis: The "Inverse" or Failure Mode (Minimal Functionality)
Enabling Description: A method of treating SCD with a "minimal effective dose" (MED) of mitapivat (e.g., mitapivat sulfate, 1 mg daily or every other day) as monotherapy, where the intention is to achieve a very subtle, yet detectable, improvement in patient biomarkers (e.g., a slight increase in Hb, minor reduction in hemolysis). This MED approach, in the absence of P-gp inhibitors, is suitable for highly sensitive patients or for long-term low-level maintenance where full therapeutic activation is not desired or tolerated. The "failure" here is the intentional lack of robust therapeutic response, instead aiming for only minimal, sustained benefit.

graph TD
    A[SCD Patient (Sensitive / Maintenance)] --> B(Administer Minimal Effective Dose Mitapivat (No P-gp Inhibitor));
    B --> C[Subtle PKR Activation];
    C --> D[Slight Improvement in Hb / Reduced Hemolysis];
    D --> E[Sustained Minimal Benefit (Minimal Functionality)];
    E --> F[Long-Term Low-Level SCD Management];

Claim 117 Derivatives: Method of treating Thalassemia with mitapivat and a p-glycoprotein inhibitor

Claim 117: A method of treating thalassemia in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof and an effective amount of a p-glycoprotein inhibitor.

Derivative 117.1: Pre-Dosing with P-gp Inhibitor for Maximal First-Pass Avoidance

Derivation Axis: Operational Parameter Expansion (Pre-Dosing Strategy)
Enabling Description: A method of treating thalassemia by administering a P-gp inhibitor (e.g., ritonavir, 100 mg) 1-2 hours prior to administering mitapivat (e.g., mitapivat sulfate, 50 mg twice daily). This pre-dosing strategy allows the P-gp inhibitor to achieve maximal inhibition of intestinal efflux pumps before mitapivat reaches the absorption site, thereby maximizing mitapivat bioavailability by preventing its first-pass efflux. This optimized timing ensures higher and more consistent mitapivat exposure, leading to improved therapeutic outcomes in thalassemia.

graph TD
    A[Thalassemia Subject] --> B(Administer P-gp Inhibitor (Ritonavir) 1-2h Pre-Mitapivat);
    B --> C[Maximal Intestinal P-gp Inhibition Achieved];
    C --> D[Administer Mitapivat];
    D --> E[Maximized Mitapivat Absorption & Bioavailability];
    E --> F[Improved Therapeutic Effect in Thalassemia];

Derivative 117.2: Dual-Release Oral Tablet with Layered P-gp Inhibitor

Derivation Axis: Material & Component Substitution (Multi-Layer Tablet)
Enabling Description: A method of treating thalassemia using a dual-release oral tablet containing mitapivat (e.g., mitapivat sulfate) and a P-gp inhibitor (e.g., quinidine). The tablet is designed with two layers: an outer immediate-release layer containing the P-gp inhibitor and an inner, slower-release core containing mitapivat. This design ensures that the P-gp inhibitor is rapidly released and starts its inhibitory action in the upper GI tract, followed by a more prolonged release of mitapivat, maximizing absorption along the intestinal length and optimizing drug exposure for thalassemia treatment.

graph TD
    A[Dual-Release Oral Tablet] --> B(Oral Administration);
    B --> C{Outer Layer Dissolution (Immediate P-gp Inhibitor Release)};
    C --> D[P-gp Inhibition in Upper GI];
    D --> E{Inner Core Dissolution (Slower Mitapivat Release)};
    E --> F[Enhanced Mitapivat Absorption Along Intestine];
    F --> G[Optimized Therapeutic Effect in Thalassemia];

Derivative 117.3: Pharmaceutical Manufacturing - Impurity Efflux Control

Derivation Axis: Cross-Domain Application (Pharmaceutical Manufacturing)
Enabling Description: A method for improving the yield and purity of a desired pharmaceutical intermediate (analogous to mitapivat) produced by microbial fermentation, where the intermediate is actively effluxed by microbial P-glycoprotein-like transporters. To counteract this, a non-toxic efflux pump inhibitor (analogous to a P-gp inhibitor, e.g., a specific fatty acid derivative) is added to the fermentation broth. This inhibitor reduces the outward transport of the intermediate, increasing its intracellular concentration and leading to higher overall production yields, streamlining the manufacturing process and reducing purification costs.

graph TD
    A[Fermentation Bioreactor (Microbial Production)] --> B(Desired Pharmaceutical Intermediate Production);
    B --> C[Microbial Efflux Pumps (Intermediate Export)];
    D[Add Efflux Pump Inhibitor to Broth];
    D --> E[Inhibition of Microbial Efflux Pumps];
    E --> F[Increased Intracellular Intermediate Concentration];
    F --> G[Higher Pharmaceutical Intermediate Yield];

Derivative 117.4: IoT-Integrated Adherence Monitoring with P-gp Inhibitor Smart Packaging

Derivation Axis: Integration with Emerging Tech (IoT Smart Packaging)
Enabling Description: A smart packaging system for co-administered mitapivat (e.g., mitapivat sulfate) and a P-gp inhibitor (e.g., itraconazole) in thalassemia patients. The packaging for both drugs is embedded with IoT sensors that detect when each pill is removed. This data is transmitted to a central hub, which monitors real-time adherence to the combined regimen. Alerts are sent to patients and caregivers for missed doses, ensuring consistent P-gp inhibition and, consequently, stable mitapivat exposure, which is critical for effective thalassemia management.

graph TD
    A[Thalassemia Patient] --> B(Smart Packaging Mitapivat);
    B --> C(Smart Packaging P-gp Inhibitor);
    C --> D[IoT Sensors: Pill Removal Detection];
    D --> E{Central Adherence Monitoring Hub};
    E --> F[Alerts for Missed Doses];
    F --> G[Consistent Co-Administration & Therapeutic Effect];

Derivative 117.5: Reversible P-gp Inhibition for "Washout" Studies

Derivation Axis: The "Inverse" or Failure Mode (Controlled Reversibility for Research)
Enabling Description: A method for conducting pharmacokinetic "washout" studies in thalassemia patients using a mitapivat (e.g., mitapivat sulfate) and a reversible P-gp inhibitor (e.g., verapamil). The "failure" here is the controlled reversal of the P-gp inhibition. After a period of co-administration, the P-gp inhibitor is acutely discontinued. By observing the rapid decline in mitapivat plasma levels (as P-gp activity quickly resumes), researchers can precisely characterize the contribution of P-gp to mitapivat's overall clearance. This controlled reversibility is a research tool to understand drug behavior, mimicking a "failure" of sustained inhibition to gain insight.

graph TD
    A[Thalassemia Subject (Research)] --> B(Mitapivat + Reversible P-gp Inhibitor (Verapamil));
    B --> C[Achieve Steady-State Mitapivat Levels];
    C --> D[Acute Discontinuation of P-gp Inhibitor];
    D --> E[Rapid Resumption of P-gp Activity];
    E --> F[Rapid Decline in Mitapivat Plasma Levels ("Washout")];
    F --> G[Characterize P-gp Contribution to Mitapivat Clearance];

Claim 124 Derivatives: Method of treating Thalassemia with mitapivat in the absence of a p-glycoprotein inhibitor

Claim 124: A method of treating thalassemia in a subject, comprising administering to the subject an effective amount of mitapivat or a pharmaceutically acceptable salt thereof in the absence of a p-glycoprotein inhibitor.

Derivative 124.1: Mitapivat with Covalent Albumin Conjugation

Derivation Axis: Material & Component Substitution (Protein Conjugation)
Enabling Description: A method of treating thalassemia by administering mitapivat (e.g., mitapivat free base) covalently conjugated to human serum albumin (HSA) via a releasable linker (e.g., an ester bond susceptible to plasma esterases). This conjugation significantly increases the circulating half-life of mitapivat and alters its distribution, effectively bypassing P-gp efflux mechanisms that might otherwise limit its bioavailability or tissue penetration. The slow release of active mitapivat from the albumin conjugate provides sustained therapeutic levels in the absence of P-gp inhibitors, optimizing treatment for thalassemia.

graph TD
    A[Mitapivat Free Base] --> B(Covalent Conjugation to HSA);
    B --> C[Mitapivat-HSA Conjugate];
    C --> D(IV Administration);
    D --> E[Increased Circulating Half-Life & Altered Distribution];
    E --> F[Slow Release of Active Mitapivat (Bypasses P-gp)];
    F --> G[Sustained Therapeutic Levels (No P-gp Inhibitor)];
    G --> H[Therapeutic Effect in Thalassemia];

Derivative 124.2: Dose Adjustment Based on Gut Microbiome Composition

Derivation Axis: Operational Parameter Expansion (Microbiome Influence)
Enabling Description: A method of treating thalassemia with mitapivat (e.g., mitapivat sulfate) in the absence of P-gp inhibitors, where the dose is adjusted based on the subject's gut microbiome composition (determined by 16S rRNA gene sequencing). Certain gut bacteria are known to metabolize or influence drug absorption and P-gp expression. For individuals with a microbiome profile predictive of low mitapivat absorption (e.g., high abundance of mitapivat-degrading bacteria or bacteria that upregulate P-gp), a higher mitapivat dose (e.g., 75-100 mg twice daily) is prescribed to compensate, ensuring adequate systemic exposure without pharmacological P-gp inhibition.

graph TD
    A[Thalassemia Subject] --> B(Gut Microbiome Analysis (16S rRNA));
    B --> C{Microbiome Profile Predictive of Low Mitapivat Absorption};
    C --> D[Adjust Mitapivat Dose (Higher Dose, No P-gp Inhibitor)];
    D --> E[Administer Mitapivat];
    E --> F[Adequate Systemic Exposure & Therapeutic Effect];

Derivative 124.3: Smart City Management - Urban Air Quality Control

Derivation Axis: Cross-Domain Application (Smart City/Environmental Monitoring)
Enabling Description: A smart city system for real-time monitoring and control of urban air quality, focusing on particulate matter (PM2.5) and ozone (O3) (analogous to mitapivat's therapeutic effect). A network of IoT air quality sensors provides continuous data. An AI-driven traffic management system adjusts traffic flow, public transport, and industrial emissions in specific zones to maintain air pollutant levels below health thresholds. The "absence of a P-gp inhibitor" implies that the system relies solely on direct reduction of pollutant sources and natural atmospheric dispersion, without chemical interventions that would alter the bioavailability or transport of a therapeutic agent, focusing on inherent environmental processes.

graph TD
    A[Urban Environment] --> B(IoT Air Quality Sensors (PM2.5, O3));
    B --> C[AI-Driven Traffic Management System];
    C --> D[Adjust Traffic Flow / Emissions (Direct Source Control)];
    D --> E[Reduced Air Pollutant Levels (No Bioavailability Modifier)];
    E --> F[Improved Urban Air Quality & Public Health];

Derivative 124.4: AI-Driven Therapeutic Switching Decisions

Derivation Axis: Integration with Emerging Tech (AI, Clinical Decision Support)
Enabling Description: An AI-powered clinical decision support system assisting physicians in deciding when to transition a thalassemia patient from a mitapivat + P-gp inhibitor regimen to mitapivat monotherapy (i.e., in the absence of a P-gp inhibitor). The AI analyzes patient response to combined therapy (e.g., sustained Hb increase, reduced transfusion burden), P-gp genotype, and other clinical markers. It predicts the likelihood of successful transition to monotherapy without loss of efficacy, providing data-driven recommendations to minimize unnecessary polypharmacy and simplify treatment for eligible patients.

graph TD
    A[Thalassemia Patient (Mitapivat + P-gp Inhibitor)] --> B(AI Clinical Decision Support System);
    B --> C[Analyze Response, Genotype, Clinical Markers];
    C --> D[Predict Success of Mitapivat Monotherapy Transition];
    D --> E{Recommendation: Transition to Monotherapy (No P-gp Inhibitor)};
    E --> F[Simplified Treatment Regimen];

Derivative 124.5: Mitapivat in a "Sub-Optimal Absorption" Diagnostic Study

Derivation Axis: The "Inverse" or Failure Mode (Diagnostic of Sub-Optimal Function)
Enabling Description: A diagnostic study designed for thalassemia patients where mitapivat (e.g., mitapivat sulfate) is administered at a standard dose in the complete absence of any P-gp inhibitors, with the specific intent of observing its sub-optimal absorption or lower-than-expected systemic exposure. This "failure" of full bioavailability is intentionally induced to identify patients with unusually high intrinsic P-gp activity or other absorption challenges. By characterizing the baseline low exposure, clinicians can then make informed decisions about whether to introduce a P-gp inhibitor or adjust mitapivat dose upwards in future therapeutic regimens.

graph TD
    A[Thalassemia Subject (Diagnostic)] --> B(Administer Mitapivat (No P-gp Inhibitor));
    B --> C[Observe & Measure Sub-Optimal Mitapivat Absorption];
    C --> D[Characterize Intrinsic P-gp Activity / Absorption Challenges];
    D --> E[Inform Future Treatment Strategies (e.g., Add Inhibitor / Increase Dose)];

Combination Prior Art Scenarios with Open-Source Standards

Here are at least 3 "Combination Prior Art" scenarios where the inventions of US Patent 11878049 are combined with existing open-source standards.

AI-Driven Personalized Dosing with FHIR (Fast Healthcare Interoperability Resources):
- Description: The AI-driven adaptive dosing system described in Derivative 1.4 (for PKD with CYP3A4/5 inducer) is integrated with an electronic health record (EHR) system adhering to the HL7 FHIR standard. IoT wearable sensors (monitoring Hb, reticulocytes, 2,3-DPG, metabolite efflux) securely transmit patient data to the EHR using FHIR resources (e.g., Observation, DeviceMetric). The AI-driven PK/PD model consumes these FHIR resources, processes them, and generates optimal mitapivat and CYP3A4/5 inducer dosage recommendations as FHIR MedicationRequest or ServiceRequest resources. This ensures seamless and standardized data exchange between devices, AI, and clinical systems, enabling personalized medicine at scale while maintaining interoperability within the healthcare ecosystem.
```
graph TD
    A[IoT Wearable Sensors] -- FHIR DeviceMetric --> B(FHIR-Compliant EHR);
    B -- FHIR Observation --> C[AI-driven PK/PD Model];
    C -- FHIR MedicationRequest --> B;
    B --> D[Smart Medication Dispenser];
    D --> E[Patient];
```
Blockchain-Secured Drug Supply Chain with OpenEHR for Clinical Auditability:
- Description: The blockchain-enabled supply chain system for mitapivat and its modulators (as mentioned in Derivative 22.4, but extended to cover both inducers and inhibitors) is combined with an OpenEHR platform for patient clinical data and auditability. Each transaction on the drug supply blockchain (manufacturer, distributor, pharmacy, patient dispensation) is cryptographically linked to a corresponding OpenEHR composition (e.g., medication administration record, adverse event report) for the individual patient. This establishes an immutable, auditable record, not only of the drug's journey but also its direct clinical context, verifying authenticity and tracing potential issues (e.g., counterfeit drugs, adverse reactions related to specific batches) across both the supply chain and patient care continuum.
```
graph TD
    A[Drug Manufacturer] -- Blockchain Transaction (Batch, Expiry) --> B(Private Blockchain Ledger);
    C[Pharmacy] -- Blockchain Transaction (Dispensation) --> B;
    B --> D[OpenEHR Platform (Clinical Context)];
    D -- OpenEHR Composition (Medication Admin, AE) --> E[Patient Record];
    E --> F[Regulatory Audit / Traceability];
```
Open-Source Linux-Based Medical Device for Optimized Mitapivat Delivery:
- Description: An advanced smart medication dispenser (as referenced in Derivative 1.4 or 16.4) for mitapivat (e.g., mitapivat sulfate) and/or its modulators runs on an open-source embedded Linux operating system (e.g., custom Yocto Linux distribution). The device's control software, responsible for precise dosing, scheduling, and communication with other IoT health devices, is developed as open-source software, adhering to relevant medical device software standards (e.g., IEC 62304 for Software of Unknown Provenance, SOUP, where applicable). This enables community-driven security patches, customizability for diverse patient needs (e.g., accessibility features), and promotes transparency in medical device functionality, while still meeting regulatory requirements for safety and efficacy.
```
graph TD
    A[Smart Medication Dispenser Hardware] --> B(Open-Source Embedded Linux OS);
    B --> C[Open-Source Control Software (IEC 62304 Compliant)];
    C --> D[Precise Drug Dispensing (Mitapivat +/- Modulator)];
    C --> E[Communication with IoT Health Devices];
    E --> F[Patient Data Collection / Feedback];
``````mermaid
graph TD
    A[Smart Medication Dispenser Hardware] --> B(Open-Source Embedded Linux OS);
    B --> C[Open-Source Control Software (IEC 62304 Compliant)];
    C --> D[Precise Drug Dispensing (Mitapivat +/- Modulator)];
    C --> E[Communication with IoT Health Devices];
    E --> F[Patient Data Collection / Feedback];
```